PT J
AU Dalbo, VJ
   Roberts, MD
   Stout, JR
   Kerksick, CM
AF Dalbo, Vincent J.
   Roberts, Michael D.
   Stout, Jeffrey R.
   Kerksick, Chad M.
TI Acute effects of ingesting a commercial thermogenic drink on changes in energy expenditure and markers of lipolysis
SO JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION
LA English
DT Article
ID caffeine ingestion; substrate utilization; food ingredients; metabolic-rate; fat oxidation; double-blind; exercise; obesity; weight; coffee
AB Background: To determine the acute effects of ingesting a thermogenic drink (Celsius, Delray Beach, FL) (TD) on changes in metabolism and lipolysis. Methods: Healthy college-aged male (23.2 +/- 4.0 y, 177.2 +/- 6.1 cm, 81.7 +/- 11.3 kg, 22.8 +/- 7.3% fat; n = 30) and female (23.4 +/- 3.1 y, 165.6 +/- 8.7 cm, 62.1 +/- 9.9 kg, 28.3 +/- 7.4% fat; n = 30) participants were matched according to height and weight to consume 336 ml of the TD or a non-caloric, non-caffeinated placebo (PLA). After a 12 h fast, participants reported for pre-consumption measures of height, weight, heart rate, blood pressure, resting energy expenditure (REE), respiratory exchange ratio (RER), glycerol and free-fatty acid (FFA) concentrations. REE and RER were determined at 60, 120, and 180 min post-consumption. Serum glycerol and FFA concentrations were determined at 30, 60, 120 and 180 min post-consumption. Results: When compared to PLA, TD significantly increased REE at 60, 120 and 180 min (p < 0.05). FFA concentrations were significantly greater in TD compared to PLA at 30, 60, 120 and 180 min post-consumption (p < 0.05). No between-group differences were found in RER. Conclusion: Acute TD ingestion significantly increased REE, FFA and glycerol appearance. If sustained, these changes may help to promote weight loss and improve body composition; however, these findings are currently unknown as are the general safety and efficacy of prolonged consumption.
C1 [Dalbo, Vincent J.; Roberts, Michael D.; Stout, Jeffrey R.; Kerksick, Chad M.] Univ Oklahoma, Dept Hlth & Exercise Sci, Norman, OK 73019 USA.
C3 University of Oklahoma System; University of Oklahoma - Norman
RP Kerksick, CM (corresponding author), Univ Oklahoma, Dept Hlth & Exercise Sci, Norman, OK 73019 USA.
EM vinnyjames@ou.edu; mike_roberts@ou.edu; jrstout@ou.edu; chad_kerksick@ou.edu
FU Celsius Inc. (Delray Beach, FL)
CR Acheson KJ, 2004, AM J CLIN NUTR, V79, P40
   ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Unknown -, 2003, HLTH AFF MILLWOOD S, V0, P0
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   BANGSBO J, 1992, J APPL PHYSIOL, V72, P1297, DOI 10.1063/1.351736
   Baron M, 2004, HLTH CARE FOOD NUTR, V21, P5
   BEAVO JA, 1970, MOL PHARMACOL, V6, P597
   BELLET S, 1968, METABOLISM, V17, P702, DOI 10.1016/0026-0495(68)90054-1
   Belza A, 2007, INT J OBESITY, V31, P121, DOI 10.1038/sj.ijo.0803351
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   COLLINS LC, 1994, INT J OBESITY, V18, P551
   Crewe HK, 2007, J CHROMATOGR B, V847, P296, DOI 10.1016/j.jchromb.2006.10.019
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Essig D, 1980, INT J SPORTS MED, V1, P86, DOI 10.1055/S-2008-1034637
   Graham TE, 1998, J APPL PHYSIOL, V85, P883, DOI 10.1152/jappl.1998.85.3.883
   GRAHAM TE, 1994, CAN J APPL PHYSIOL, V19, P111, DOI 10.1139/h94-010
   Graham TE, 2000, J PHYSIOL-LONDON, V529, P837, DOI 10.1111/j.1469-7793.2000.00837.x
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hoffman Jay R, 2006, J INT SOC SPORTS NUTR, V3, P35, DOI 10.1186/1550-2783-3-1-35
   Jessen AB, 2003, AM J CLIN NUTR, V77, P1442, DOI 10.1093/ajcn/77.6.1442
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Knapik JJ, 1983, BIOCHEM EXERC, V13, P514
   Kovacs EMR, 2006, OBES REV, V7, P59, DOI 10.1111/j.1467-789X.2006.00203.x
   LEBLANC J, 1985, J APPL PHYSIOL, V59, P832, DOI 10.1152/jappl.1985.59.3.832
   Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523
   Pittler MH, 2004, AM J CLIN NUTR, V79, P529
   POEHLMAN ET, 1985, MED SCI SPORT EXER, V17, P689, DOI 10.1249/00005768-198512000-00012
   POWERS SK, 1985, SPORTS MED, V2, P165, DOI 10.2165/00007256-198502030-00002
   POWERS SK, 1983, EUR J APPL PHYSIOL, V50, P301, DOI 10.1007/BF00423236
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Roth M, 2000, BIOL CHEM, V381, P269, DOI 10.1515/BC.2000.035
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Ryu S, 2001, J NUTR SCI VITAMINOL, V47, P139, DOI 10.3177/jnsv.47.139
   Stein CJ, 2004, J CLIN ENDOCR METAB, V89, P2522, DOI 10.1210/jc.2004-0288
   TAYLOR LW, 2007, J INT SOC SPORTS NUT, V4, P0
   vanSoeren M, 1996, J APPL PHYSIOL, V80, P999, DOI 10.1152/jappl.1996.80.3.999
   WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007
   Wolpoff M, 1998, EVOL ANTHROPOL, V7, P1
NR 42
TC 26
Z9 28
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1550-2783
J9 J INT SOC SPORT NUTR
JI J. Int. Soc. Sport Nutr.
PD FEB 20
PY 2008
VL 5
IS 
BP 
EP 
DI 10.1186/1550-2783-5-6
PG 7
WC Nutrition & Dietetics; Sport Sciences
SC Nutrition & Dietetics; Sport Sciences
GA 486NS
UT WOS:000269204500001
PM 18289388
DA 2025-04-28
ER

PT J
AU Nakabayashi, H
   Hashimoto, T
   Ashida, H
   Nishiumi, S
   Kanazawa, K
AF Nakabayashi, Hideo
   Hashimoto, Takashi
   Ashida, Hitoshi
   Nishiumi, Shin
   Kanazawa, Kazuki
TI Inhibitory effects of caffeine and its metabolites on intracellular lipid accumulation in murine 3T3-L1 adipocytes
SO BIOFACTORS
LA English
DT Article; Proceedings Paper
DE Caffeine; caffeine metabolites; 3T3-L1 adipocytes; glucose uptake; adipocyte differentiation
ID glucose-transport; green tea; partial clearances; insulin; rat; differentiation; expression; cells; adipogenesis; allopurinol
AB To understand the mechanisms of the anti-obesity effects of dietary caffeine, the effects of caffeine and its metabolites on adipocyte differentiation and insulin-stimulated glucose uptake in murine 3T3-L1 adipocytes were investigated. Caffeine did not inhibit the differentiation of 3T3-L1 pre-adipocytes to mature adipocytes, but it did suppress the intracellular lipid accumulation after complete differentiation in a dose-dependent manner (0.125-1.0 mM). This effect was also observed in 1,3,7-trimethyluric acid-3,7-dimethyluric acid-and 5-acetylamino-6-formylamino-3-methyluracil-treated cells. Caffeine also inhibited insulin-stimulated glucose uptake in differentiated 3T3-L1 adipocytes in a dose-dependent manner. Treatment with theophylline, paraxanthine, 1-methylxanthine (MX), 3-MX, or 7-MX also inhibited glucose uptake in differentiated adipocytes. These results suggest that the anti-obesity activity of dietary caffeine is due to the additive and/or synergistic inhibitory effects of caffeine and its metabolites on intracellular lipid accumulation and that caffeine does not affect adipocyte differentiation.
C1 [Nakabayashi, Hideo; Hashimoto, Takashi; Ashida, Hitoshi; Nishiumi, Shin; Kanazawa, Kazuki] Kobe Univ, Grad Sch Agr Sci, Kobe, Hyogo 657, Japan.
C3 Kobe University
RP Hashimoto, T (corresponding author), 1-1 Rokkodai, Kobe, Hyogo 6578501, Japan.
EM takashi@kobe-u.ac.jp
CR Akiba T, 2004, BIOCHEM PHARMACOL, V68, P1929, DOI 10.1016/j.bcp.2004.07.036
   Arnaud MJ, 1993, CAFFEINE COFFEE HLTH, V0, P43
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Baumann CA, 2001, BIOESSAYS, V23, P215, DOI 10.1002/1521-1878(200103)23:3<215::AID-BIES1031>3.0.CO;2-S
   BENOWITZ NL, 1990, ANNU REV MED, V41, P277, DOI 10.1146/annurev.me.41.020190.001425
   BUKOWIECKI LJ, 1983, AM J PHYSIOL, V244, PR500, DOI 10.1152/ajpregu.1983.244.4.R500
   CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538
   CHOI OH, 1988, LIFE SCI, V43, P387, DOI 10.1016/0024-3205(88)90517-6
   FLEDHOLM BB, 1978, BIOCHEM PHARMACOL, V27, P2845
   GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783
   GRYGIEL JJ, 1979, CLIN PHARMACOL THER, V26, P660
   Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200
   Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200
   Hasegawa N, 2000, J HEALTH SCI, V46, P153
   Hinds TS, 1996, NUTR REV, V54, P203, DOI 10.1111/j.1753-4887.1996.tb03933.x
   JOOST HG, 1987, MOL PHARMACOL, V31, P279
   KALOW W, 1993, CLIN PHARMACOL THER, V53, P503, DOI 10.1038/clpt.1993.63
   KALOW W, 1991, CLIN PHARMACOL THER, V49, P44, DOI 10.1038/clpt.1991.8
   KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685
   KIMURA K, 1994, J BIOL CHEM, V269, P18961
   LELO A, 1986, BRIT J CLIN PHARMACO, V22, P183, DOI 10.1111/j.1365-2125.1986.tb05247.x
   LELO A, 1989, J PHARMACOL EXP THER, V248, P315
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590
   Michna L, 2003, LIFE SCI, V73, P1383, DOI 10.1016/S0024-3205(03)00468-5
   MINERS JO, 1982, DRUG METAB DISPOS, V10, P672
   PARSONS WD, 1976, PEDIATR RES, V10, P333
   STEINFELDER HJ, 1990, BIOCHEM PHARMACOL, V40, P1154, DOI 10.1016/0006-2952(90)90508-I
   TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   VERGAUWEN L, 1994, J CLIN INVEST, V93, P974, DOI 10.1172/JCI117104
   WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Zheng GD, 2004, IN VIVO, V18, P55
NR 38
TC 43
Z9 45
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-6433
EI 1872-8081
J9 BIOFACTORS
JI Biofactors
PD JUN 15
PY 2008
VL 34
IS 4
BP 293
EP 302
DI 10.1002/biof.5520340405
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 509NT
UT WOS:000271025400005
PM 19850984
DA 2025-04-28
ER

PT J
AU Gerhauser, C
AF Gerhauser, Clarissa
TI Cancer Chemopreventive Potential of Apples, Apple juice, and Apple Components
SO PLANTA MEDICA
LA English
DT Review
DE apples; Malus sp.; Rosaceae; cancer chemoprevention; oligomeric procyanidins; polyphenols
ID plasma antioxidant capacity; pomace extraction juices; growth-factor receptor; kappa-b activation; dna-damage; hydrogen-peroxide; chlorogenic acid; malus-pumila; in-vitro; antiproliferative activity
AB Apples (Malus sp., Rosaceae) are a rich source of nutrient as well as non-nutrient components and contain high levels of polyphenols and other phytochemicals. Main structural classes of apple constituents include hydroxycinnamic acids, di-hydrochalcones, flavonols (quercetin glycosides), catechins and oligomeric procyaniclins, as well as triterpenoids in apple peel and anthocyanins in red apples. Several lines of evidence suggest that apples and apple products possess a wide range of biological activities which may contribute to health beneficial effects against cardiovascular disease, asthma and pulmonary dysfunction, diabetes, obesity, and cancer (reviewed by Boyer and Liu, Nutr J 2004). The present review will summarize the current knowledge on potential cancer preventive effects of apples, apple juice and apple extracts (jointly designated as apple products). In brief, apple extracts and components, especially oligomeric procyanidins, have been shown to influence multiple mechanisms relevant for cancer prevention in in vitro studies. These include antimutagenic activity, modulation of carcinogen metabolism, antioxidant activity, anti-inflammatory mechanisms, modulation of signal transduction pathways, antiproliferative and apoptosis-inducing activity, as well as novel mechanisms on epigenetic events and innate immunity. Apple products have been shown to prevent skin, mammary and colon carcinogenesis in animal models. Epidemiological observations indicate that regular consumption of one or more apples a day may reduce the risk for lung and colon cancer.
C1 German Canc Res Ctr, Div Toxicol & Canc Risk Factors, D-9120 Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ)
RP Gerhauser, C (corresponding author), German Canc Res Ctr, Div Toxicol & Canc Risk Factors, Neuenheimer Feld 280, D-9120 Heidelberg, Germany.
EM c.gerhauser@dkfz.de
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363
   Akazome Y, 2004, BIOFACTORS, V22, P311, DOI 10.1002/biof.5520220161
   Akiyama H, 2005, FEBS LETT, V579, P4485, DOI 10.1016/j.febslet.2005.07.019
   Alonso-Salces RM, 2004, J AGR FOOD CHEM, V52, P2938, DOI 10.1021/jf035416l
   Aprikian O, 2003, J NUTR, V133, P1860, DOI 10.1093/jn/133.6.1860
   Aron PM, 2008, MOL NUTR FOOD RES, V52, P79, DOI 10.1002/mnfr.200700137
   Arts ICW, 2001, INT J CANCER, V92, P298, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1187>3.0.CO;2-8
   Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647
   Barth SW, 2007, J AGR FOOD CHEM, V55, P1181, DOI 10.1021/jf063078t
   Barth SW, 2005, CARCINOGENESIS, V26, P1414, DOI 10.1093/carcin/bgi082
   Boyer J, 2004, NUTR J, V3, P0, DOI 10.1186/1475-2891-3-5
   Briviba K, 2007, J AGR FOOD CHEM, V55, P7716, DOI 10.1021/jf0710534
   Burda S, 2001, J AGR FOOD CHEM, V49, P2774, DOI 10.1021/jf001413m
   Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH-23.487
   Chen MS, 2004, IN VIVO, V18, P73
   Chinnici F, 2004, J AGR FOOD CHEM, V52, P4684, DOI 10.1021/jf049770a
   Chrzczanowicz J, 2008, CLIN CHEM LAB MED, V46, P342, DOI 10.1515/CCLM.2008.062
   Crespy V, 2001, J NUTR, V131, P3227, DOI 10.1093/jn/131.12.3227
   Crespy V, 2001, J NUTR, V131, P2109, DOI 10.1093/jn/131.8.2109
   DAngelo S, 2007, J AGR FOOD CHEM, V55, P9977, DOI 10.1021/jf071773a
   Davie JR, 2003, J NUTR, V133, P2485S, DOI 10.1093/jn/133.7.2485S
   Davis PA, 2006, EXP BIOL MED, V231, P594
   De Flora S, 2005, MUTAT RES-FUND MOL M, V591, P8, DOI 10.1016/j.mrfmmm.2005.02.029
   DeneoPellegrini H, 1996, NUTR CANCER, V25, P297, DOI 10.1080/01635589609514453
   Déprez S, 2000, J NUTR, V130, P2733, DOI 10.1093/jn/130.11.2733
   Ding M, 2004, J BIOL CHEM, V279, P10670, DOI 10.1074/jbc.M311465200
   Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148
   Ellinger W, 2007, ZMP MARKTBILANZ OBST, V0, P0
   Fang MZ, 2007, J NUTR, V137, P223S, DOI 10.1093/jn/137.1.223S
   FERGUSON LR, 1994, MUTAT RES, V307, P395, DOI 10.1016/0027-5107(94)90313-1
   Ferguson LR, 2003, FOOD CHEM TOXICOL, V41, P785, DOI 10.1016/S0278-6915(03)00012-7
   Feskanich D, 2000, JNCI-J NATL CANCER I, V92, P1812, DOI 10.1093/jnci/92.22.1812
   Fini L, 2007, J NUTR, V137, P2622, DOI 10.1093/jn/137.12.2622
   Fridrich D, 2007, MOL NUTR FOOD RES, V51, P594, DOI 10.1002/mnfr.200600189
   Frighetto RTS, 2008, FOOD CHEM, V106, P767, DOI 10.1016/j.foodchem.2007.06.003
   Gallus S, 2005, ANN ONCOL, V16, P1841, DOI 10.1093/annonc/mdi361
   Gerhäuser C, 2008, EJC SUPPL, V6, P50, DOI 10.1016/S1359-6349(08)70258-1
   Gerhäuser C, 2003, MUTAT RES-FUND MOL M, V523, P163, DOI 10.1016/S0027-5107(02)00332-9
   GERHAUSER C, 2007, FORUM DTSCH KREBSGES, V0, P5
   Gonthier MP, 2003, J NUTR, V133, P1853, DOI 10.1093/jn/133.6.1853
   Goodlad RA, 2007, NUTRITION, V23, P434, DOI 10.1016/j.nut.2006.10.010
   Gossé F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074
   Gossé F, 2006, INT J ONCOL, V29, P423
   Graff JC, 2007, J LEUKOCYTE BIOL, V82, P603, DOI 10.1189/jlb.0207125
   Gu LW, 2004, J NUTR, V134, P613, DOI 10.1093/jn/134.3.613
   Guyot S, 2003, J AGR FOOD CHEM, V51, P6240, DOI 10.1021/jf0301798
   Guyot S, 2001, J AGR FOOD CHEM, V49, P14, DOI 10.1021/jf000814z
   Guyot S, 1998, J AGR FOOD CHEM, V46, P1698, DOI 10.1021/jf970832p
   He XJ, 2007, J AGR FOOD CHEM, V55, P4366, DOI 10.1021/jf063563o
   Hensel A, 1999, PLANTA MED, V65, P395, DOI 10.1055/s-1999-14013
   Hibasami H, 2004, INT J MOL MED, V13, P795
   Hoffmann Raymond G, 2007, V404, V0, PP19, DOI 10.1007/978-1-59745-530-5_2
   Holderness J, 2007, J IMMUNOL, V179, P6468, DOI 10.4049/jimmunol.179.10.6468
   Huemmer Wolfgang, 2008, BIOTECHNOL J, V3, P234, DOI 10.1002/biot.200700116
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Kahle K, 2005, MOL NUTR FOOD RES, V49, P1143, DOI 10.1002/mnfr.200500132
   Kahle K, 2005, MOL NUTR FOOD RES, V49, P797, DOI 10.1002/mnfr.200500064
   Kahle K, 2007, J AGR FOOD CHEM, V55, P10605, DOI 10.1021/jf071942r
   Kang NJ, 2004, BIOFACTORS, V21, P361, DOI 10.1002/biof.552210169
   Kelloff GJ, 2006, CLIN CANCER RES, V12, P3661, DOI 10.1158/1078-0432.CCR-06-1104
   Kern M, 2005, MOL NUTR FOOD RES, V49, P317, DOI 10.1002/mnfr.200400086
   Kern M, 2007, J AGR FOOD CHEM, V55, P4999, DOI 10.1021/jf063158x
   Kern M, 2006, J AGR FOOD CHEM, V54, P7041, DOI 10.1021/jf0606611
   Kestell P, 2004, J CHROMATOGR B, V802, P201, DOI 10.1016/j.jchromb.2003.10.046
   Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4
   Knekt P, 2002, AM J CLIN NUTR, V76, P560, DOI 10.1093/ajcn/76.3.560
   Ko SH, 2005, J MED FOOD, V8, P41, DOI 10.1089/jmf.2005.8.41
   Köhle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009
   Lapidot T, 2002, J AGR FOOD CHEM, V50, P3156, DOI 10.1021/jf011522g
   Lata B, 2005, J AGR FOOD CHEM, V53, P8970, DOI 10.1021/jf051503x
   Lata B, 2007, J AGR FOOD CHEM, V55, P10795, DOI 10.1021/jf072035p
   Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154
   Lee KW, 2003, J AGR FOOD CHEM, V51, P6516, DOI 10.1021/jf034475w
   Lee Se Young, 2005, KOREAN J GASTROENTEROL, V45, P23
   Lindblad P, 1997, CANCER EPIDEM BIOMAR, V6, P215
   Liu RH, 2005, J AGR FOOD CHEM, V53, P2341, DOI 10.1021/jf058010c
   Liu RH, 2003, J AGR FOOD CHEM, V51, P1718, DOI 10.1021/jf026162r
   Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895
   Lotito SB, 2004, FREE RADICAL BIO MED, V36, P201
   Lotito SB, 2004, FREE RADICAL BIO MED, V37, P251, DOI 10.1016/j.freeradbiomed.2004.04.019
   Lotito SB, 2006, FREE RADICAL BIO MED, V41, P1727, DOI 10.1016/j.freeradbiomed.2006.04.033
   Maffei F, 2007, BRIT J NUTR, V97, P921, DOI 10.1017/S0007114507665192
   Maldonado-Celis ME, 2008, CELL MOL LIFE SCI, V65, P1425, DOI 10.1007/s00018-008-8023-4
   Manach C, 2005, AM J CLIN NUTR, V81, P230S, DOI 10.1093/ajcn/81.1.230S
   MANDIR N, 2008, BR J NUTR, V0, P1
   Mangas JJ, 1997, J AGR FOOD CHEM, V45, P4777, DOI 10.1021/jf970262t
   Mayer B, 2001, ANAL BIOCHEM, V297, P144, DOI 10.1006/abio.2001.5333
   McCann MJ, 2007, FOOD CHEM TOXICOL, V45, P1224, DOI 10.1016/j.fct.2007.01.003
   McGhie TK, 2005, J AGR FOOD CHEM, V53, P3065, DOI 10.1021/jf047832r
   Mehrländer K, 2002, J AGR FOOD CHEM, V50, P1230, DOI 10.1021/jf011007i
   Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734
   Michels KB, 2006, CANCER RES, V66, P3942, DOI 10.1158/0008-5472.CAN-05-3637
   Milner JA, 2006, NUTR CANCER, V56, P216, DOI 10.1207/s15327914nc5602_13
   Miura D, 2007, BIOSCI BIOTECH BIOCH, V71, P2743, DOI 10.1271/bbb.70359
   Miura T, 2008, CARCINOGENESIS, V29, P585, DOI 10.1093/carcin/bgm198
   MULERONAVARRO S, 2008, CRIT REV ONCOL HEMAT, V0, P0, DOI DOI 10.1016/J.CRI-TREVONC.2008.03.001
   OHKAMI H, 1995, JPN J CANCER RES, V86, P523, DOI 10.1111/j.1349-7006.1995.tb02429.x
   OhnishiKameyama M, 1997, RAPID COMMUN MASS SP, V11, P31, DOI 10.1002/(SICI)1097-0231(19970115)11:1<31::AID-RCM784>3.0.CO;2-T
   Olthof MR, 2003, J NUTR, V133, P1806, DOI 10.1093/jn/133.6.1806
   Olthof MR, 2001, J NUTR, V131, P66, DOI 10.1093/jn/131.1.66
   Oszmianski J, 2007, J SCI FOOD AGR, V87, P573, DOI 10.1002/jsfa.2707
   Ovesná Z, 2004, NEOPLASMA, V51, P327
   OWEN R W, 1987, NUTRITION AND CANCER, V9, P67
   Pan L, 2005, CANCER EPIDEM BIOMAR, V14, P0
   Park SY, 2007, J MED FOOD, V10, P581, DOI 10.1089/jmf.2007.116
   Pearson DA, 1999, LIFE SCI, V64, P1913, DOI 10.1016/S0024-3205(99)00137-X
   Percival SS, 2008, J NUTR, V138, P1
   Pohl C, 2006, J AGR FOOD CHEM, V54, P10262, DOI 10.1021/jf061791c
   Prior RL, 2005, PHYTOCHEMISTRY, V66, P2264, DOI 10.1016/j.phytochem.2005.03.025
   Ramos S, 2008, MOL NUTR FOOD RES, V52, P507, DOI 10.1002/mnfr.200700326
   Rios LY, 2002, AM J CLIN NUTR, V76, P1106, DOI 10.1093/ajcn/76.5.1106
   Sanoner P, 1999, J AGR FOOD CHEM, V47, P4847, DOI 10.1021/jf990563y
   Scalbert A, 2000, J NUTR, V130, P2073S, DOI 10.1093/jn/130.8.2073S
   Schaefer S, 2006, MOL NUTR FOOD RES, V50, P24, DOI 10.1002/mnfr.200500136
   Schmitz-Eiberger M, 2003, J APPL BOT-ANGEW BOT, V77, P167
   Sembries S, 2004, J NUTR BIOCHEM, V15, P296, DOI 10.1016/j.jnutbio.2003.12.005
   Sembries S, 2003, BRIT J NUTR, V90, P607, DOI 10.1079/BJN2003925
   Sembries S, 2006, J AGR FOOD CHEM, V54, P10269, DOI 10.1021/jf0618168
   Sengupta S, 2006, J GASTROEN HEPATOL, V21, P209, DOI 10.1111/j.1440-1746.2006.04213.x
   Shi David, 2002, JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, V21, P233
   Shibusawa Y, 2001, J CHROMATOGR A, V915, P253, DOI 10.1016/S0021-9673(01)00575-1
   Shimizu J, 1996, J NUTR SCI VITAMINOL, V42, P527, DOI 10.3177/jnsv.42.527
   Shoji T, 2006, J CHROMATOGR A, V1102, P206, DOI 10.1016/j.chroma.2005.10.065
   Shoji T, 2004, FOOD CHEM TOXICOL, V42, P959, DOI 10.1016/j.fct.2004.02.008
   Souci SW, 2005, FOOD COMPOSITION NUT, V0, P0
   Spencer JPE, 2001, ANTIOXID REDOX SIGN, V3, P1023, DOI 10.1089/152308601317203558
   SPORN MB, 1979, FED PROC, V38, P2528
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Theodoratou E, 2007, CANCER EPIDEM BIOMAR, V16, P684, DOI 10.1158/1055-9965.EPI-06-0785
   Thielen C, 2004, DEUT LEBENSM-RUNDSCH, V100, P389
   Trosko JE, 2006, CONTRIB MICROBIOL, V13, P45, DOI 10.1159/000092965
   Tsao R, 2003, J AGR FOOD CHEM, V51, P6347, DOI 10.1021/jf0346298
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Van Buren J, 1970, THE BIOCHEMISTRY OF FRUITS AND THEIR PRODUCTS, V0, P0
   van der Sluis AA, 2000, J AGR FOOD CHEM, V48, P4116, DOI 10.1021/jf000156i
   Vanzani P, 2005, J AGR FOOD CHEM, V53, P3377, DOI 10.1021/jf040482o
   Veeriah S, 2006, MOL CARCINOGEN, V45, P164, DOI 10.1002/mc.20158
   Veeriah S, 2008, INT J CANCER, V122, P2647, DOI 10.1002/ijc.23440
   Veeriah S, 2007, J AGR FOOD CHEM, V55, P2892, DOI 10.1021/jf063386r
   Vermeulen K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x
   Vrhovsek U, 2004, J AGR FOOD CHEM, V52, P6532, DOI 10.1021/jf049317z
   Waldecker M, 2008, NUTRITION, V24, P366, DOI 10.1016/j.nut.2007.12.013
   Walle T, 2000, J NUTR, V130, P2658, DOI 10.1093/jn/130.11.2658
   Walle Thomas, 2001, JOURNAL OF NUTRITION, V131, P2648
   Will F, 2000, EUR FOOD RES TECHNOL, V211, P291, DOI 10.1007/s002170000171
   Wilms LC, 2005, MUTAT RES-GEN TOX EN, V582, P155, DOI 10.1016/j.mrgentox.2005.01.006
   Wilms LC, 2007, CARCINOGENESIS, V28, P1800, DOI 10.1093/carcin/bgm145
   *WIRTSCH ALK GETR, 2008, PROKOPF VERBR ALK GE, V0, P0
   Wolfe KL, 2003, J AGR FOOD CHEM, V51, P1676, DOI 10.1021/jf025916z
   Yanagida A, 1999, J CHROMATOGR A, V855, P181, DOI 10.1016/S0021-9673(99)00684-6
   Yanagida A, 2000, J CHROMATOGR A, V890, P251, DOI 10.1016/S0021-9673(00)00614-2
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611
   Yoon H, 2007, J AGR FOOD CHEM, V55, P3167, DOI 10.1021/jf0632379
   Zessner H, 2008, MOL NUTR FOOD RES, V52, PS28, DOI 10.1002/mnfr.200700317
NR 158
TC 196
Z9 219
U1 9
U2 104
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD OCT 15
PY 2008
VL 74
IS 13
BP 1608
EP 1624
DI 10.1055/s-0028-1088300
PG 17
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 370RT
UT WOS:000260781300010
PM 18855307
DA 2025-04-28
ER

PT J
AU Dallas, C
   Gerbi, A
   Tenca, G
   Juchaux, F
   Bernard, FX
AF Dallas, Constantin
   Gerbi, Alain
   Tenca, Guillaume
   Juchaux, Franck
   Bernard, Francois-Xavier
TI Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE)
SO PHYTOMEDICINE
LA English
DT Article
DE Lipolysis; Citrus; Adipocytes; Phosphodiesterase; Body fat; Free fatty acids (FFA)
ID model wine solutions; green tea; oligomeric procyanidins; rat adipocytes; 3t3-l1 cells; anthocyanins; acetaldehyde; consumption; substances; flavonoids
AB The present study investigated the lipolytic (break of fat stored) effect of a citrus-based polyphenolic dietary supplement (SINETROL) at human adipocytes (ex vivo), body fat (clinical) and biochemical levels (inhibition of phosphodiesterase). Free fatty acids (FFA) release was used as indicator of human adipocyte lipolysis and SINETROL activity has been compared with known lipolytic products (isoproterenol, theopylline and caffeine). SINETROL stimulated significantly the lipolytic activity in a range of 6 fold greater than the control. Moreover, SINETROL has 2.1 greater activity than guarana 12% caffeine while its content in caffeine is 3 times lower. Clinically, two groups of 10 volunteers with BMI relevant of overweight were compared during 4 and 12 weeks with 1.4 g/day SINETROL and placebo supplementation. In the SINETROL Group the body fat (%) decreased with a significant difference of 5.53% and 15.6% after 4 and 12 weeks, respectively, while the body weight (kg) decreased with a significant difference of 2.2 and 5.2 kg after 4 and 12 weeks, respectively. These observed effects are linked to SINETROL polyphenolic composition and its resulting synergistic activity. SINETROL is a potent inhibitor of cAMP-phosphodiesterase (PDE) (97%) compared to other purified compounds (cyanidin-3 glycoside, narangin, caffeine). These results suggest that SINETROL has a strong lipolytic effect mediated by cAMP-PDE inhibition. SINETROL may serve to prevent obesity by decreasing BMI. (C) 2008 Elsevier GmbH. All rights reserved.
C1 [Dallas, Constantin] FYTEXIA NB Consulting Grp, ZAC Mercorent, F-34500 Beziers, France.
   [Tenca, Guillaume; Juchaux, Franck; Bernard, Francois-Xavier] BIOalternat SAS, F-86160 Gencay, France.
RP Dallas, C (corresponding author), FYTEXIA NB Consulting Grp, ZAC Mercorent, 280 Rue Nicolas Joseph Cugnot, F-34500 Beziers, France.
EM cdallas@fytexia.com
CR Balkau B, 2007, CIRCULATION, V116, P1942, DOI 10.1161/CIRCULATIONAHA.106.676379
   Ballard TLP, 2006, CLIN EXP PHARMACOL P, V33, P310, DOI 10.1111/j.1440-1681.2006.04367.x
   BEAVO JA, 1971, ANN NY ACAD SCI, V185, P129
   Chen D, 2004, FRONT BIOSCI-LANDMRK, V9, P2618, DOI 10.2741/1421
   Dallas C, 1996, J AGR FOOD CHEM, V44, P2402, DOI 10.1021/jf940433j
   Dallas C, 1995, VITIS, V34, P51
   DALLAS C, 1994, J SCI FOOD AGR, V65, P477, DOI 10.1002/jsfa.2740650416
   Dallas C, 1996, J SCI FOOD AGR, V70, P493, DOI 10.1002/(SICI)1097-0010(199604)70:4<493::AID-JSFA528>3.3.CO;2-Z
   DALLAS C, 1994, VITIS, V33, P41
   FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V
   Fujioka K, 2006, J MED FOOD, V9, P49, DOI 10.1089/jmf.2006.9.49
   Girotti C, 2005, PLANTA MED, V71, P1170, DOI 10.1055/s-2005-873146
   Jiang M, 1998, PLANTA MED, V64, P375, DOI 10.1055/s-2006-957456
   KUPPUSAMY UR, 1992, BIOCHEM PHARMACOL, V44, P1307, DOI 10.1016/0006-2952(92)90531-M
   LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U
   Mochizuki M, 2004, PHYTOTHER RES, V18, P1029, DOI 10.1002/ptr.1612
   Mochizuki M, 2004, PHYTOTHER RES, V18, P945, DOI 10.1002/ptr.1580
   Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185
   RENOLD AE, 1965, HDB PHYSL 5, V0, P0
   Robidoux J, 2006, J BIOL CHEM, V281, P37794, DOI 10.1074/jbc.M605572200
   RODBELL M, 1964, J BIOL CHEM, V239, P375
   Shixian Q, 2006, J MED FOOD, V9, P451, DOI 10.1089/jmf.2006.9.451
   SPECTOR AA, 1975, J LIPID RES, V16, P165
   STEINBERG D, 1977, FED PROC, V36, P1986
   Tsuda T, 2005, BBA-MOL CELL BIOL L, V1733, P137, DOI 10.1016/j.bbalip.2004.12.014
   Yoshikawa M, 2002, J NUTR, V132, P1819, DOI 10.1093/jn/132.7.1819
NR 26
TC 64
Z9 74
U1 2
U2 38
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944-7113
EI 
J9 PHYTOMEDICINE
JI Phytomedicine
PD OCT 15
PY 2008
VL 15
IS 10
BP 783
EP 792
DI 10.1016/j.phymed.2008.05.006
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 364RG
UT WOS:000260352200001
PM 18617377
DA 2025-04-28
ER

PT J
AU Moisey, LL
   Kacker, S
   Bickerton, AC
   Robinson, LE
   Graham, TE
AF Moisey, Lesley L.
   Kacker, Sita
   Bickerton, Andrea C.
   Robinson, Lindsay E.
   Graham, Terry E.
TI Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID type-2 diabetes-mellitus; tolerance test; insulin sensitivity; risk; ingestion; humans; women; management; increases; secretion
AB Background: The ingestion of caffeine (5 mg/kg body weight) and a 75-g oral glucose load has been shown to elicit an acute insulin-insensitive environment in healthy and obese individuals and in those with type 2 diabetes. Objective: In this study we investigated whether a similar impairment in blood glucose management exists when coffee and foods typical of a Western diet were used in a similar protocol. Design: Ten healthy men underwent 4 trials in a randomized order. They ingested caffeinated (5 mg/kg) coffee (CC) or the same volume of decaffeinated coffee (DC) followed 1 h later by either a high or low glycemic index (GI) cereal (providing 75 g of carbohydrate) mixed meal tolerance test. Results: CC with the high GI meal resulted in 147%, 29%, and 40% greater areas under the curve for glucose (P < 0.001), insulin (NS), and C-peptide (P < 0.001), respectively, compared with the values for DC. Similarly, with the low GI treatment, CC elicited 216%, 44%, and 36% greater areas under the curve for glucose (P < 0.001), insulin (P < 0.01), and C-peptide (P < 0.01), respectively. Insulin sensitivity was significantly reduced (40%) with the high GI treatment after CC was ingested compared with DC; with the low GI treatment, CC ingestion resulted in a 29% decrease in insulin sensitivity, although this difference was not significant. Conclusion: The ingestion of CC with either a high or low GI meal significantly impairs acute blood glucose management and insulin sensitivity compared with ingestion of DC. Future investigations are warranted to determine whether CC is a risk factor for insulin resistance.
C1 [Moisey, Lesley L.; Kacker, Sita; Bickerton, Andrea C.; Robinson, Lindsay E.; Graham, Terry E.] Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada.
C3 University of Guelph
RP Graham, TE (corresponding author), Univ Guelph, Dept Human Hlth & Nutr Sci, Guelph, ON N1G 2W1, Canada.
EM terrygra@uoguelph.ca
CR Agardh EE, 2004, J INTERN MED, V255, P645, DOI 10.1111/j.1365-2796.2004.01331.x
   ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245
   Unknown -, 2003, CANADIAN DIABETES AS, V27, P0
   Avogaro A, 1996, DIABETES, V45, P1373, DOI 10.2337/diabetes.45.10.1373
   Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   BATTRAM DS, 2000, J PHYSL, V583, P1069
   Brand-Miller J, 2003, DIABETES CARE, V26, P2261, DOI 10.2337/diacare.26.8.2261
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   Farah A, 2006, J AGR FOOD CHEM, V54, P374, DOI 10.1021/jf0518305
   FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x
   GILBERT RM, 1984, METHYLXANTHINE BEVER, V0, P185
   Graham TE, 1998, J APPL PHYSIOL, V85, P883, DOI 10.1152/jappl.1998.85.3.883
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Harland BF, 2000, NUTRITION, V16, P522, DOI 10.1016/S0899-9007(00)00369-5
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Lane James D, 2007, ENDOCR PRACT, V13, P239
   Lane JD, 2004, DIABETES CARE, V27, P2047, DOI 10.2337/diacare.27.8.2047
   LOWRY OH, 1993, ENZYMATIC ANAL PRACT, V0, P0
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840
   Pereira MA, 2006, ARCH INTERN MED, V166, P1311, DOI 10.1001/archinte.166.12.1311
   Petrie HJ, 2004, AM J CLIN NUTR, V80, P22
   Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657
   Robinson LE, 2004, J NUTR, V134, P2528, DOI 10.1093/jn/134.10.2528
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Shearer J, 2007, CAN J PHYSIOL PHARM, V85, P823, DOI 10.1139/Y07-070
   Shearer J, 2003, J NUTR, V133, P3529, DOI 10.1093/jn/133.11.3529
   SPILLER MA, 1984, METHYLXANTHINE BEVER, V0, P91
   Thong FSL, 2007, APPL PHYSIOL NUTR ME, V32, P701, DOI 10.1139/H07-039
   Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2006, DIABETES CARE, V29, P398, DOI 10.2337/diacare.29.02.06.dc05-1512
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846
   Yamaji T, 2004, DIABETOLOGIA, V47, P2145, DOI 10.1007/s00125-004-1590-5
NR 40
TC 93
Z9 102
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAY 15
PY 2008
VL 87
IS 5
BP 1254
EP 1261
DI 10.1093/ajcn/87.5.1254
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 301EZ
UT WOS:000255880500022
PM 18469247
DA 2025-04-28
ER

PT J
AU Ito, Y
   Ichikawa, T
   Morohosh, Y
   Nakamura, T
   Saegusa, Y
   Ishihara, K
AF Ito, Yuko
   Ichikawa, Takafumi
   Morohosh, Yasuo
   Nakamura, Takeshi
   Saegusa, Yoichi
   Ishihara, Kazuhiko
TI Effect of tea catechins on body fat accumulation in rats fed a normal diet
SO BIOMEDICAL RESEARCH-TOKYO
LA English
DT Article
ID cholesterol-fed rats; green tea; energy-expenditure; lipid-metabolism; adipose-tissue; caffeine; thermogenesis; polyphenols; activation; extracts
AB Although it is known that tea catechins exert potent effects in obese subjects, there is scant information concerning these effects on body weight gain and body fat accumulation in the non-obese. We studied normal rats fed a normal diet and water containing either 0.1% or 0.5% tea catechins to examine the effects on body fat content and serum cholesterol levels, as well as evaluating whether the effect is related to bile acids, which in recent years have emerged as an inducer of energy expenditure. The administration of 0.5% catechins decreased the accumulation of body fat and the serum levels of cholesterol and bile acids. These results indicate that tea catechins modulate lipid metabolism not only in obese subjects, but also in the non-obese.
C1 [Ito, Yuko; Ishihara, Kazuhiko] Kitasato Univ, Sch Allied Hlth Sci, Dept Biochem, Sagamihara, Kanagawa 2288555, Japan.
   [Ichikawa, Takafumi] Kitasato Univ, Sch Med, Dept Biochem, Sagamihara, Kanagawa 2288555, Japan.
   [Morohosh, Yasuo] Kitasato Univ, Sch Med, Dept Lab Anim Sci, Sagamihara, Kanagawa 2288555, Japan.
   [Nakamura, Takeshi] Kitasato Univ, Sch Med, Dept Parasitol, Sagamihara, Kanagawa 2288555, Japan.
   [Saegusa, Yoichi] Kitasato Univ, Sch Med, Dept Internal Med, Sagamihara, Kanagawa 2288555, Japan.
C3 Kitasato University; Kitasato University; Kitasato University; Kitasato University; Kitasato University
RP Ishihara, K (corresponding author), Kitasato Univ, Sch Allied Hlth Sci, Dept Biochem, 1-15-1 kitasato, Sagamihara, Kanagawa 2288555, Japan.
EM yukodietitian@yahoo.co.jp
CR Carr DB, 2004, DIABETES, V53, P2087, DOI 10.2337/diabetes.53.8.2087
   CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X
   Chen ZY, 2001, J AGR FOOD CHEM, V49, P477, DOI 10.1021/jf000877h
   Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   FOLCH J, 1963, BIOL CHEM, V226, P497
   FRIED SK, 1987, INT J OBESITY, V11, P129
   Hasegawa N, 2003, PHYTOTHER RES, V17, P477, DOI 10.1002/ptr.1177
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   IKEMOTO S, 1997, J AM PHYSL, V273, P0
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Lin JK, 1998, J AGR FOOD CHEM, V46, P3635, DOI 10.1021/jf980223x
   MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   REBUFFESCRIVE M, 1989, METABOLISM, V38, P453, DOI 10.1016/0026-0495(89)90198-4
   Sano J, 2004, CIRC J, V68, P665, DOI 10.1253/circj.68.665
   Sato H, 2002, J GASTROENTEROL, V37, P106, DOI 10.1007/s005350200004
   Sayama K, 2000, IN VIVO, V14, P481
   Seto R, 1997, BIOSCI BIOTECH BIOCH, V61, P1434, DOI 10.1271/bbb.61.1434
   Suzuki Y, 2005, BIOSCI BIOTECH BIOCH, V69, P1288, DOI 10.1271/bbb.69.1288
   Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   Yang MH, 2001, J NUTR BIOCHEM, V12, P14, DOI 10.1016/S0955-2863(00)00140-6
   Yang TTC, 1999, LIFE SCI, V66, P411, DOI 10.1016/S0024-3205(99)00607-4
   Yokozawa T, 2002, J AGR FOOD CHEM, V50, P3549, DOI 10.1021/jf020029h
   Zheng GD, 2004, IN VIVO, V18, P55
NR 28
TC 39
Z9 42
U1 0
U2 6
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA 15-NISHI 7, SAPPORO, 060-8638, JAPAN
SN 0388-6107
EI 1880-313X
J9 BIOMED RES-TOKYO
JI Biomed. Res.
PD FEB 15
PY 2008
VL 29
IS 1
BP 27
EP 32
DI 10.2220/biomedres.29.27
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 273JQ
UT WOS:000253926600004
PM 18344595
DA 2025-04-28
ER

PT J
AU Ohishi, W
   Fujiwara, S
   Cologne, JB
   Suzuki, G
   Akahoshi, M
   Nishi, N
   Takahashi, I
   Chayama, K
AF Ohishi, Waka
   Fujiwara, Saeko
   Cologne, John B.
   Suzuki, Gen
   Akahoshi, Masazurni
   Nishi, Nobuo
   Takahashi, Ikuno
   Chayama, Kazuaki
TI Risk factors for hepatocellular carcinoma in a Japanese population: A nested case-control study
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID chronic hepatitis-c; liver-cancer; insulin-resistance; selecting controls; virus-infections; viral-hepatitis; alcohol; obesity; cohort; fibrosis
AB Background: Epidemiologic studies have shown effects of lifestyle-related factors on risk for hepatocellular carcinoma. However, few cohort studies have incorporated, in a strict and in-depth manner, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections or investigated synergism between such factors. Methods: We conducted a nested case-control study using sera stored before hepatocellular carcinoma diagnosis in the longitudinal cohort of atomic bomb survivors. The study included 224 hepatocellular carcinoma cases and 644 controls that were matched to the cases on gender, age, city, time of serum storage, and method of serum storage, and countermatched on radiation dose. Results: Univariate analysis showed that HBV and HCV infections, alcohol consumption, smoking habit, body mass index (BMI), and diabetes mellitus were associated with increased hepatocellular carcinoma risk, whereas coffee drinking was associated with decreased hepatocellular carcinoma risk. Multivariate relative risks of hepatocellular carcinoma (95% confidence interval) were 45.8 (15.2-138), 101 (38.7-263), 70.7 (8.3-601), 4.36 (1.48-13.0), and 4.57 (1.85-11.3), for HBV infection alone, HCV infection alone, both HBV and HCV infections, alcohol consumption of >= 40 g of ethanol per day, and BMI of >25.0 kg/m(2) 10 years before diagnosis, respectively. HBV and HCV infection and BMI of >25.0 kg/m(2) remained independent risk factors even after adjusting for severity of liver fibrosis. Among HCV-infected individuals, the relative risk of hepatocellular carcinoma for a 1 kg/m(2) increase in BMI was 1.39 (P = 0.003). Conclusions: To limit the risk for hepatocellular carcinoma, control of excess weight may be crucial for individuals with chronic liver disease, especially those with chronic hepatitis C.
C1 [Ohishi, Waka; Fujiwara, Saeko; Suzuki, Gen; Akahoshi, Masazurni; Takahashi, Ikuno] Radiat Effects Res Fdn, Dept Clin Studies, Minami Ku, Hiroshima 7320815, Japan.
   [Cologne, John B.] Radiat Effects Res Fdn, Dept Stat, Hiroshima 7320815, Japan.
   [Nishi, Nobuo] Radiat Effects Res Fdn, Dept Epidemiol, Hiroshima 7320815, Japan.
   [Chayama, Kazuaki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Div Frontier Med Sci,Programs Biomed Res, Hiroshima, Japan.
   [Suzuki, Gen] Natl Inst Publ Hlth, Dept Environm Hlth, Wako, Saitama, Japan.
C3 Radiation Effects Research Foundation - Japan; Radiation Effects Research Foundation - Japan; Radiation Effects Research Foundation - Japan; Hiroshima University; National Institute of Public Health - Japan
RP Ohishi, W (corresponding author), Radiat Effects Res Fdn, Dept Clin Studies, Minami Ku, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan.
EM nwaka@rerf.or.jp
CR Aizawa Y, 2000, CANCER, V89, P53, DOI 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.0.CO;2-6
   Unknown -, 2000, ASIA PACIFIC PERSPEC, V0, P0
   Unknown -, 1980, CLASSICAL METHODS AN, V0, P0
   Bugianesi E, 2005, HEPATOLOGY, V42, P987, DOI 10.1002/hep.20920
   Bullock RE, 2004, J HEPATOL, V41, P685, DOI 10.1016/j.jhep.2004.05.008
   Caldwell SH, 2004, GASTROENTEROLOGY, V127, PS97, DOI 10.1053/j.gastro.2004.09.021
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Cologne J, 2003, J EPIDEMIOL, V13, P193, DOI 10.2188/jea.13.193
   Cologne JB, 2004, INT J EPIDEMIOL, V33, P485, DOI 10.1093/ije/dyh097
   COLOGNE JB, 1995, EPIDEMIOLOGY, V6, P271, DOI 10.1097/00001648-199505000-00014
   Cologne JE, 1999, RADIAT RES, V152, P364, DOI 10.2307/3580221
   Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2
   Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323
   El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065
   Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639
   Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7
   Fukuhara T, 2001, J RADIAT RES, V42, P117, DOI 10.1269/jrr.42.117
   Gupta K, 2002, AM J MED SCI, V323, P140, DOI 10.1097/00000441-200203000-00004
   Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780
   Hu KQ, 2004, J HEPATOL, V40, P147, DOI 10.1016/S0168-8278(03)00479-3
   *IARC, 2004, IARC MON EC CARC RIS, V83, P0
   Inoue M, 2005, JNCI-J NATL CANCER I, V97, P293, DOI 10.1093/jnci/dji040
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Ioannou GN, 2007, CLIN GASTROENTEROL H, V5, P938, DOI 10.1016/j.cgh.2007.02.039
   IWAHASHI K, 1995, ALCOHOL CLIN EXP RES, V19, P564, DOI 10.1111/j.1530-0277.1995.tb01549.x
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kiyosawa K, 2004, GASTROENTEROLOGY, V127, PS17, DOI 10.1053/j.gastro.2004.09.012
   LANGHOLZ B, 1995, BIOMETRIKA, V82, P69
   Marrero JA, 2005, J HEPATOL, V42, P218, DOI 10.1016/j.jhep.2004.10.005
   Monto A, 2004, HEPATOLOGY, V39, P826, DOI 10.1002/hep.20127
   Moriya K, 2001, CANCER RES, V61, P4365
   Nair S, 2002, HEPATOLOGY, V36, P150, DOI 10.1053/jhep.2002.33713
   Oh SW, 2005, J CLIN ONCOL, V23, P4742, DOI 10.1200/JCO.2005.11.726
   Ohishi W, 2003, SCAND J GASTROENTERO, V38, P894, DOI 10.1080/00365520310004434
   Ohishi W, 2007, RES ADV MICROBIOLOGY, V7, P1
   Ohishi W, 2006, J CLIN MICROBIOL, V44, P4593, DOI 10.1128/JCM.00621-06
   Perumalswami P, 2006, HEPATOLOGY, V43, P780, DOI 10.1002/hep.21078
   Pohl A, 2001, AM J GASTROENTEROL, V96, P3142, DOI 10.1111/j.1572-0241.2001.05268.x
   Ruhl CE, 2005, GASTROENTEROLOGY, V128, P24, DOI 10.1053/j.gastro.2004.09.075
   Sharp GB, 2005, INT J CANCER, V115, P290, DOI 10.1002/ijc.20897
   Shintani Y, 2004, GASTROENTEROLOGY, V126, P840, DOI 10.1053/j.gastro.2003.11.056
   TANAKA T, 1990, BASIC LIFE SCI, V52, P429
   Wang LY, 1998, AM J EPIDEMIOL, V147, P315
   YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987
   Young RW, 2005, REASSESSMENT ATOMIC, V0, P0
   Yu MC, 2004, GASTROENTEROLOGY, V127, PS72, DOI 10.1016/j.gastro.2004.09.018
   Yuan JM, 2004, CANCER, V101, P1009, DOI 10.1002/cncr.20427
NR 47
TC 85
Z9 91
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD APR 15
PY 2008
VL 17
IS 4
BP 846
EP 854
DI 10.1158/1055-9965.EPI-07-2806
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 288EM
UT WOS:000254969000016
PM 18398026
DA 2025-04-28
ER

PT J
AU Pang, J
   Choi, Y
   Park, T
AF Pang, Jisook
   Choi, Youngshim
   Park, Taesun
TI Ilex paraguariensis extract ameliorates obesity induced by high-fat diet:: Potential role of AMPK in the visceral adipose tissue
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Ilex paraguariensis; high-fat diet; anti-obesity effect; AMPK; ACC; UCP2; UCP3; epididymal adipose tissue; rat
ID green tea; body-weight; caffeine; expression; cholesterol; gene; acid; thermogenesis; gamma; rats
AB The aim of present study was to investigate the anti-obesity effect of Ilex paraguariensis extract and its molecular mechanism in rats rendered obese by a high-fat diet (HFD). T paraguariensis extract supplementation significantly lowered body weight, visceral fat-pad weights, blood and hepatic lipid, glucose, insulin, and leptin levels of rats administered HFD. Feeding I. paraguariensis extract reversed the HFD-induced downregulation of the epididymal adipose tissue genes implicated in adipogenesis or thermogenesis, such as peroxisome proliferators' activated receptor gamma 2, adipocyte fatty acid binding protein, sterol-regulatory-element-binding protein-1c, fatty acid synthase, HMG-CoA reductase, uncoupling protein 2, and uncoupling protein 3. Dietary supplementation with I. paraguariensis extract protected rats from the HFD-induced decreases in the phospho-AMP-activated protein kinase (AMPK)/AMPK and phospho-acetylCoA carboxylase (ACC)/ACC protein ratio related to fatty acid oxidation in the edipidymal adipose tissue. The present study reports that the I. paraguariensis extract can have a protective effect against a HFD-induced obesity in rats through an enhanced expression of uncoupling proteins and elevated AMPK phosphorylation in the visceral adipose tissue. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Pang, Jisook; Choi, Youngshim; Park, Taesun] Yonsei Univ, Dept Food & Nutr, Brain Korea Project 21, Seoul 120749, South Korea.
C3 Yonsei University
RP Park, T (corresponding author), Yonsei Univ, Dept Food & Nutr, Brain Korea Project 21, 134 Shinchon Dong, Seoul 120749, South Korea.
EM tspark@yonsei.ac.kr
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Andersen T, 2001, J HUM NUTR DIET, V14, P243, DOI 10.1046/j.1365-277X.2001.00290.x
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   BABA N, 1982, AM J CLIN NUTR, V35, P678, DOI 10.1093/ajcn/35.4.678
   Bixby M, 2005, LIFE SCI, V77, P345, DOI 10.1016/j.lfs.2004.11.030
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   Diraison F, 2002, AM J PHYSIOL-ENDOC M, V282, PE46, DOI 10.1152/ajpendo.2002.282.1.E46
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Emilsson V, 2000, METABOLISM, V49, P1610, DOI 10.1053/meta.2000.18692
   Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5
   Ferreira F, 1997, PHYTOTHER RES, V11, P79, DOI 10.1002/(SICI)1099-1573(199702)11:1<79::AID-PTR34>3.3.CO;2-I
   Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Han UK, 2002, J NUTR, V132, P2241, DOI 10.1093/jn/132.8.2241
   HETZLER RK, 1990, J APPL PHYSIOL, V68, P44, DOI 10.1152/jappl.1990.68.1.44
   HOSTTETMANN K, 1995, SAPONINS, V0, P0
   Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920
   Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096
   Kogure A, 2002, CLIN EXP PHARMACOL P, V29, P391, DOI 10.1046/j.1440-1681.2002.03675.x
   Kraemer KH, 1996, PHYTOCHEMISTRY, V42, P1119, DOI 10.1016/0031-9422(96)00036-2
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V83, P674, DOI 10.1093/ajcn.83.3.674
   Matsuda J, 1998, DIABETES, V47, P1809, DOI 10.2337/diabetes.47.11.1809
   Mosimann ALP, 2006, BIOFACTORS, V26, P59, DOI 10.1002/biof.5520260106
   Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371
   OAKENFULL DG, 1984, NUTR REP INT, V29, P1039
   Pittler MH, 2005, OBES REV, V6, P93, DOI 10.1111/j.1467-789X.2005.00169.x
   Pomilio AB, 2002, PHYTOCHEM ANALYSIS, V13, P235, DOI 10.1002/pca.647
   Rosen ED, 2005, PROSTAG LEUKOTR ESS, V73, P31, DOI 10.1016/j.plefa.2005.04.004
   Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715
   Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006-1055
   Stein FLP, 2005, BIOL RES NURS, V7, P146, DOI 10.1177/1099800405280521
   Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061
   Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045
   Tripathy D, 2003, DIABETES, V52, P2882, DOI 10.2337/diabetes.52.12.2882
   Unger RH, 2004, CELL, V117, P145, DOI 10.1016/S0092-8674(04)00339-3
   VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740
   Woods SC, 2003, J NUTR, V133, P1081, DOI 10.1093/jn/133.4.1081
   World Health Organisation, 2002, WORLD HLTH REPORT 20, V0, P0
   Zheng GD, 2004, IN VIVO, V18, P55
NR 40
TC 116
Z9 121
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD AUG 15
PY 2008
VL 476
IS 2
BP 178
EP 185
DI 10.1016/j.abb.2008.02.019
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 337GW
UT WOS:000258424500012
PM 18314006
DA 2025-04-28
ER

PT J
AU Reddy, JG
   Ebbert, JO
   Klesges, LM
   Enders, FTB
   Klesges, RC
   Lanctot, JQ
   McClanahan, BS
AF Reddy, Jagadeshwar G.
   Ebbert, Jon O.
   Klesges, Lisa M.
   Enders, Felicity T. B.
   Klesges, Robert C.
   Lanctot, Jennifer Q.
   McClanahan, Barbara S.
TI THE RELATIONSHIP BETWEEN CAFFEINE AND BLOOD PRESSURE IN PREADOLESCENT AFRICAN AMERICAN GIRLS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Caffeine; Child; Blood Pressure; African Americans; Risk Factors
ID cardiovascular risk-factors; dietary assessment; coffee-drinking; heart-rate; children; hypertension; adolescents; overweight; association; tolerance
AB Background: While high caffeine consumption has been shown to be associated with increased blood pressure in controlled experiments, the relationship between caffeine consumption and blood pressure in preadolescent (ages 6-11 years) and adolescent (ages 12-19 years) children has not been well studied. The primary objective of this study was to assess the cross-sectional relationship between caffeine intake and blood pressure in 8- to 10-year-old African American girls who eat an unrestricted diet. Methods: Demographic, 24-hour dietary recall, and blood pressure data collected at baseline from 303 African American girls aged 8-10 years in the Girls health Enrichment Multisite Studies (GEMS) cohort were analyzed by using linear and multiple regression models. Results: Dietary caffeine intake was not associated with either systolic or diastolic blood pressure (P= .33 and P = .36, respectively). However, consistent with the literature, height and body mass index were each positively and independently associated with systolic blood pressure (both P<.0001). Height and amount of sodium intake were positively associated with diastolic blood pressure (P = .01 and P = .02, respectively). Conclusions: Dietary caffeine intake in low amounts is not associated with elevated blood pressure in 8- to 10-year-old African American girls who eat an unrestricted diet. (Ethn Dis. 2008; 18:283-288)
C1 [Reddy, Jagadeshwar G.; Ebbert, Jon O.; Klesges, Lisa M.; Enders, Felicity T. B.; Klesges, Robert C.] Mayo Clin, Coll Med, Rochester, MN 55905 USA.
   [Lanctot, Jennifer Q.; McClanahan, Barbara S.] Univ Memphis, Memphis, TN 38152 USA.
C3 Mayo Clinic; University of Memphis
RP Reddy, JG (corresponding author), Mayo Clin, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.
EM reddy.jagadeshwar@mayo.edu
FU National Heart, Lung, and Blood Institute [HL62662]
CR AMMON HPT, 1983, BRIT J CLIN PHARMACO, V15, P701, DOI 10.1111/j.1365-2125.1983.tb01553.x
   Burke V, 2005, INT J OBESITY, V29, P15, DOI 10.1038/sj.ijo.0802750
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Cullen KW, 2004, PREV MED, V38, PS34, DOI 10.1016/j.ypmed.2003.05.002
   Cullen KW, 2004, PREV MED, V38, PS24, DOI 10.1016/j.ypmed.2003.05.001
   Daniels JW, 1998, J APPL PHYSIOL, V85, P154, DOI 10.1152/jappl.1998.85.1.154
   Daniels SR, 1998, HYPERTENSION, V31, P97, DOI 10.1161/01.HYP.31.1.97
   Daniels SR, 1998, CIRCULATION, V97, P1907, DOI 10.1161/01.CIR.97.19.1907
   Dekkers JC, 2002, J PEDIATR-US, V141, P770, DOI 10.1067/mpd.2002.128113
   ECK LH, 1989, J AM DIET ASSOC, V89, P784
   Eldridge AL, 1998, J AM DIET ASSOC, V98, P777, DOI 10.1016/S0002-8223(98)00175-8
   FAUST HS, 1982, AM J CLIN NUTR, V35, P1459, DOI 10.1093/ajcn/35.6.1459
   Ford ES, 2004, PEDIATRICS, V114, P1534, DOI 10.1542/peds.2004-0674
   Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175
   Genovesi S, 2005, J HYPERTENS, V23, P493, DOI 10.1097/01.hjh.0000160203.35910.9f
   Green PJ, 1996, J BEHAV MED, V19, P111, DOI 10.1007/BF01857602
   James JE, 2004, PSYCHOPHYSIOLOGY, V41, P914, DOI 10.1111/j.1469-8986.2004.00248.x
   Jee SH, 1999, HYPERTENSION, V33, P647, DOI 10.1161/01.HYP.33.2.647
   Lane JD, 1998, PSYCHOSOM MED, V60, P327, DOI 10.1097/00006842-199805000-00019
   Lovallo WR, 2004, HYPERTENSION, V43, P760, DOI 10.1161/01.HYP.0000120965.63962.93
   LYTLE LA, 1993, J AM DIET ASSOC, V93, P1431, DOI 10.1016/0002-8223(93)92247-U
   Morrison JA, 1999, J PEDIATR-US, V135, P451, DOI 10.1016/S0022-3476(99)70167-8
   Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555
   NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302
   Obarzanek Eva, 2003, ETHNICITY & DISEASE, V13, P0
   Paradis G, 2004, CIRCULATION, V110, P1832, DOI 10.1161/01.CIR.0000143100.31752.B7
   PINCOMB GA, 1985, AM J CARDIOL, V56, P119, DOI 10.1016/0002-9149(85)90578-8
   Rochon James, 2003, ETHN DIS, V13, P0
   Savoca MR, 2005, AM J HYPERTENS, V18, P116, DOI 10.1016/j.amjhyper.2004.08.011
   Savoca MR, 2004, ARCH PEDIAT ADOL MED, V158, P473, DOI 10.1001/archpedi.158.5.473
   SCHAKEL SF, 1988, J AM DIET ASSOC, V88, P1268
   SIEVERT YA, 1989, CONTROL CLIN TRIALS, V10, P416, DOI 10.1016/0197-2456(89)90006-8
   SimonsMorton DG, 1997, PEDIATR NEPHROL, V11, P244, DOI 10.1007/s004670050271
   SINAIKO AR, 1993, HYPERTENSION, V21, P989, DOI 10.1161/01.HYP.21.6.989
   Sorof JM, 2004, PEDIATRICS, V113, P475, DOI 10.1542/peds.113.3.475
   Sorof JM, 2002, J PEDIATR-US, V140, P660, DOI 10.1067/mpd.2002.125228
   Sung BH, 1995, AM J HYPERTENS, V8, P1184, DOI 10.1016/0895-7061(95)00331-2
   VANHORN LV, 1990, J AM DIET ASSOC, V90, P412
   VANHORN LV, 1993, J AM DIET ASSOC, V93, P1396, DOI 10.1016/0002-8223(93)92241-O
   Verma M, 1994, INDIAN PEDIATR, V31, P1065
   Waring WS, 2003, AM J HYPERTENS, V16, P919, DOI 10.1016/S0895-7061(03)01014-8
   Watson J, 2002, BRIT J CLIN PHARMACO, V54, P400, DOI 10.1046/j.1365-2125.2002.01681.x
   Wilson Dawn K, 1999, ETHNICITY AND DISEASE, V9, P350
   Winkelmayer WC, 2005, JAMA-J AM MED ASSOC, V294, P2330, DOI 10.1001/jama.294.18.2330
NR 45
TC 5
Z9 6
U1 0
U2 9
PU ETHNICITY & DISEASE, INC
PI OWINGS MILL
PA 9812 SHERWOOD FARM RD, OWINGS MILL, MD, UNITED KINGDOM
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM 15
PY 2008
VL 18
IS 3
BP 283
EP 288
DI 
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 489MC
UT WOS:000269423200003
PM 18785440
DA 2025-04-28
ER

PT J
AU Jalil, AMM
   Ismail, A
   Pei, CP
   Hamid, M
   Kamaruddin, SHS
AF Jalil, Abbe Maleyki Mhd
   Ismail, Amin
   Pei, Chong Pei
   Hamid, Muhajir
   Kamaruddin, Syed Hasbullah Syed
TI Effects of cocoa extract on glucometabolism, oxidative stress, and antioxidant enzymes in obese-diabetic (Ob-db) rats
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE caffeine; catalase; catechin; cocoa; epicatechin; superoxide dismutase; theobromine
ID 2nd-phase insulin-secretion; cacao liquor; glucose-levels; theobroma-cacao; lipid profiles; powder; diet; chocolate; humans; atherosclerosis
AB In this present study, we investigated the effects of cocoa extract containing polyphenols and methylxanthines prepared from cocoa powder on the biochemical parameters of obese-diabetic (Ob-db) rats. Obese-diabetic (Ob-db) rats were developed using a high-fat diet (49% fat, 32% carbohydrate, and 19% protein from total energy, kcal) for 3 months, followed by a low dose (35 mg/kg body weight) streptozotocin (STZ) injection. Cocoa extract (600 mg/kg body weight/day) was given to the rats for 4 weeks. The results indicated that there were no significant differences in fasting plasma glucose and insulin level after 4 weeks of cocoa extract administration. Oral glucose tolerance test revealed that cocoa supplementation in Ob-db rats significantly (p < 0.05) reduced plasma glucose at 60 and 90 min compared to unsupplemented Ob-db rats. Plasma free fatty acid and oxidative stress biomarker (8-isoprostane) were significantly (p < 0.05) reduced after cocoa supplementation. Superoxide dismutase activity was enhanced in Ob-db compared to that in nonsupplemented rats. However, no change was observed in catalase activity. The results showed that cocoa supplementation had an effect on postprandial glucose control but not for long term (4 weeks). Moreover, cocoa supplementation could reduce circulating plasma free fatty acid and 8-isoprostane and may enhance the antioxidant defense system.
C1 [Jalil, Abbe Maleyki Mhd; Ismail, Amin; Kamaruddin, Syed Hasbullah Syed] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Malaysia.
   [Pei, Chong Pei] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Malaysia.
   [Hamid, Muhajir] Univ Putra Malaysia, Dept Microbiol, Fac Biotechnol & Biomol Sci, Serdang 43400, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia
RP Ismail, A (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Malaysia.
EM amin@medic.upm.edu.my
CR Amin I, 2004, NUTRITION & FOOD SCIENCE, V34, P116, DOI 10.1108/00346650410536737
   Amin I, 2004, J MED FOOD, V7, P7, DOI 10.1089/109662004322984635
   Baba S, 2007, J NUTR, V137, P1436, DOI 10.1093/jn/137.6.1436
   Bisson JF, 2008, EUR J CANCER PREV, V17, P54, DOI 10.1097/CEJ.0b013e3280145b33
   Brand-Miller J, 2003, J NUTR, V133, P3149, DOI 10.1093/jn/133.10.3149
   *CMA, 2008, COC CHOC RES, V0, P0
   Colak E, 2008, BIOCHEM MEDICA, V18, P42
   Dillinger TL, 2000, J NUTR, V130, P2057S, DOI 10.1093/jn/130.8.2057S
   Fehse F, 2005, J CLIN ENDOCR METAB, V90, P5991, DOI 10.1210/jc.2005-1093
   Joo Soon-Jae, 1995, JOURNAL OF APPLIED NUTRITION, V47, P67
   Kanaya Y, 2004, DIABETES RES CLIN PR, V66, PS157, DOI 10.1016/j.diabres.2003.09.021
   Kelm MA, 2006, J AGR FOOD CHEM, V54, P1571, DOI 10.1021/jf0525941
   Kumari K, 2007, J ETHNOPHARMACOL, V109, P367, DOI 10.1016/j.jep.2006.07.045
   Kurosawa T, 2005, J ATHEROSCLER THROMB, V12, P20, DOI 10.5551/jat.12.20
   Lecumberri E, 2007, NUTRITION, V23, P332, DOI 10.1016/j.nut.2007.01.013
   Malstrom B, 1975, ENZYMES B, VXIIB, P533
   Natsume M, 2000, BIOSCI BIOTECH BIOCH, V64, P2581, DOI 10.1271/bbb.64.2581
   Osakabe N, 1998, J NUTR SCI VITAMINOL, V44, P313, DOI 10.3177/jnsv.44.313
   Pankow JS, 2004, DIABETES CARE, V27, P77, DOI 10.2337/diacare.27.1.77
   PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909
   Quddusi S, 2003, DIABETES CARE, V26, P791, DOI 10.2337/diacare.26.3.791
   Ramiro-Puig E, 2007, J AGR FOOD CHEM, V55, P6431, DOI 10.1021/jf070487w
   Ruzaidi A, 2005, J ETHNOPHARMACOL, V98, P55, DOI 10.1016/j.jep.2004.12.018
   Ruzaidi AMM, 2008, J SCI FOOD AGR, V88, P1442, DOI 10.1002/jsfa.3236
   Song FF, 2007, CLIN SCI, V112, P599, DOI 10.1042/CS20060323
   Srinivasan K, 2007, INDIAN J MED RES, V125, P451
   Tomaru M, 2007, NUTRITION, V23, P351, DOI 10.1016/j.nut.2007.01.007
   Tomas-Barberán FA, 2007, J AGR FOOD CHEM, V55, P3926, DOI 10.1021/jf070121j
   Vinson JA, 1999, J AGR FOOD CHEM, V47, P4821, DOI 10.1021/jf990312p
   Yamagishi M, 2001, LIPIDS, V36, P67, DOI 10.1007/s11745-001-0669-9
NR 30
TC 72
Z9 79
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD SEP 10
PY 2008
VL 56
IS 17
BP 7877
EP 7884
DI 10.1021/jf8015915
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 344OU
UT WOS:000258938000044
PM 18702467
DA 2025-04-28
ER

PT J
AU Hughes, LAE
   Arts, ICW
   Ambergen, T
   Brants, HAM
   Dagnelie, PC
   Goldbohm, RA
   van den Brandt, PA
   Weijenberg, MP
AF Hughes, Laura A. E.
   Arts, Ilja C. W.
   Ambergen, Ton
   Brants, Henny A. M.
   Dagnelie, Pieter C.
   Goldbohm, R. Alexandra
   van den Brandt, Piet A.
   Weijenberg, Matty P.
TI Higher dietary flavone, flavonol, and catechin intakes are associated with less of an increase in BMI over time in women: a longitudinal analysis from the Netherlands Cohort Study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID self-reported height; potentially anticarcinogenic flavonoids; scale prospective cohort; green tea; fat oxidation; cardiovascular risk; prevents obesity; body-weight; consumption; anthocyanins
AB Background: Dietary flavonoids are suggested to have antiobesity effects. Prospective evidence of an association between flavonoids and body mass index (BMI) is lacking in general populations. Objective: We assessed this association between 3 flavonoid subgroups and BMI over a 14-y period in 4280 men and women aged 55-69 y at baseline from the Netherlands Cohort Study. Design: Dietary intake was estimated at baseline (1986) by a validated food-frequency questionnaire. BMI was ascertained through self-reported height (in 1986) and weight (in 1986, 1992, and 2000). Analyses were based on sex-specific quintiles for the total intake of 6 catechins and of 3 flavonols/flavones. Linear mixed effect modeling was used to assess longitudinal associations in 3 adjusted models: age only, lifestyle (age, energy intake, physical activity, smoking status, alcohol intake, type 2 diabetes, and coffee consumption), and lifestyle and diet (vegetables, fruit, fiber, grains, sugar, dessert, and dieting habits). Results: After adjustment for age and confounders, the BMI(kg/m(2)) of women with the lowest intake of total flavonols/flavones and total catechins increased by 0.95 and 0.77, respectively, after 14 y. Women with the highest intake of total flavonols/flavones and total catechins experienced a significantly lower increase in BMI of 0.40 and 0.31, respectively (between group difference: P < 0.05). This difference remained after additional adjustment for dietary determinants and after stratification of median baseline BMI. In men, no significant differences in BMI change were observed over the quintiles of flavonoid intake after 14 y. Conclusion: Our results suggest that flavonoid intake may contribute to maintaining body weight in the general female population. Am J Clin Nutr 2008; 88: 1341-52.
C1 [Hughes, Laura A. E.] Maastricht Univ, Fac Hlth Med & Life Sci, Dept Epidemiol, Sch Oncol & Dev Biol GROW, NL-6200 MD Maastricht, Netherlands.
   [Arts, Ilja C. W.; Dagnelie, Pieter C.] Maastricht Univ, Nutr & Toxicol Res Inst, NUTRIM, Maastricht, Netherlands.
   [Ambergen, Ton] Univ Maastricht, Dept Methodol & Stat, Maastricht, Netherlands.
   [Brants, Henny A. M.] TNO Qual Life, Dept Food & Chem Risk Anal, Zeist, Netherlands.
   [Goldbohm, R. Alexandra] TNO Qual Life, Dept Prevent & Hlth, Zeist, Netherlands.
C3 Maastricht University; Maastricht University; Maastricht University; Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research
RP Hughes, LAE (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Dept Epidemiol, Sch Oncol & Dev Biol GROW, POB 616, NL-6200 MD Maastricht, Netherlands.
EM laura.hughes@epid.unimaas.nl.s
FU Dutch Cancer Society; Netherlands Organization for Scientific Research-Earth and Life Sciences
CR Abidov M, 2006, GEORGIAN MED NEWS, V0, P66
   Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643
   Aron PM, 2008, MOL NUTR FOOD RES, V52, P79, DOI 10.1002/mnfr.200700137
   Arts ICW, 2000, J AGR FOOD CHEM, V48, P1746, DOI 10.1021/jf000025h
   Arts ICW, 2000, J AGR FOOD CHEM, V48, P1752, DOI 10.1021/jf000026+
   Arts ICW, 2005, AM J CLIN NUTR, V81, P317S, DOI 10.1093/ajcn/81.1.317S
   Arts ICW, 2001, EUR J CLIN NUTR, V55, P76, DOI 10.1038/sj.ejcn.1601115
   Bolton-Smith C, 2000, J EPIDEMIOL COMMUN H, V54, P143, DOI 10.1136/jech.54.2.143
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   Chang NS, 2002, BMC CELL BIOL, V3, P0, DOI 10.1186/1471-2121-3-8
   Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005
   Czernichow S, 2002, INT J OBESITY, V26, P1138, DOI 10.1038/sj.ijo.0802059
   de Boer VCJ, 2006, CELL MOL LIFE SCI, V63, P2847, DOI 10.1007/s00018-006-6316-z
   Diepvens K, 2006, PHYSIOL BEHAV, V87, P185, DOI 10.1016/j.physbeh.2005.09.013
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Finucane Mariel M, 2007, EPIDEMIOL PERSPECT INNOV, V4, P8, DOI 10.1186/1742-5573-4-8
   Frank T, 2003, CAN J PHYSIOL PHARM, V81, P423, DOI 10.1139/y03-038
   Galati G, 2006, FREE RADICAL BIO MED, V40, P570, DOI 10.1016/j.freeradbiomed.2005.09.014
   GOLDBOHM RA, 1995, EUR J CLIN NUTR, V49, P420
   GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253
   Goldbohm RA, 1997, POLYPHENOLS FOOD, V0, P159
   Henning SM, 2004, AM J CLIN NUTR, V80, P1558
   HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267
   HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011
   HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   HOLBROOK TL, 1989, INT J OBESITY, V13, P723
   Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4
   Holt RR, 2006, J CARDIOVASC PHARM, V47, PS187, DOI 10.1097/00005344-200606001-00014
   Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001
   Ikeda I, 2005, BIOSCI BIOTECH BIOCH, V69, P1049, DOI 10.1271/bbb.69.1049
   IMAI K, 1995, BRIT MED J, V310, P693, DOI 10.1136/bmj.310.6981.693
   Kono S, 1996, J EPIDEMIOL, V6, P128
   Kwon SH, 2007, J MED FOOD, V10, P552, DOI 10.1089/jmf.2006.147
   MAZZA G, 2007, ANTHOCYANINS CARDIOV, V0, P0
   Nyholm M, 2007, OBESITY, V15, P197, DOI 10.1038/oby.2007.536
   Ong KC, 2000, LIFE SCI, V67, P1695, DOI 10.1016/S0024-3205(00)00758-X
   Palermo CM, 2003, CHEM RES TOXICOL, V16, P865, DOI 10.1021/tx025672c
   Panico S, 2008, PREV MED, V47, P53, DOI 10.1016/j.ypmed.2008.01.023
   Peterson J, 1998, NUTR RES, V18, P1995, DOI 10.1016/S0271-5317(98)00169-9
   Phillips SM, 2003, INT J OBESITY, V27, P1106, DOI 10.1038/sj.ijo.0802370
   Pischon T, 2006, J NATL CANCER I, V98, P920, DOI 10.1093/jnci/djj246
   Prior RL, 2008, J AGR FOOD CHEM, V56, P647, DOI 10.1021/jf071993o
   Prior RL, 2006, FREE RADICAL RES, V40, P1014, DOI 10.1080/10715760600758522
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Sampson L, 2002, J AM DIET ASSOC, V102, P1414, DOI 10.1016/S0002-8223(02)90314-7
   Schmidt M, 2005, FOOD CHEM TOXICOL, V43, P307, DOI 10.1016/j.fct.2004.11.001
   Soobrattee MA, 2005, MUTAT RES-FUND MOL M, V579, P200, DOI 10.1016/j.mrfmmm.2005.03.023
   Spencer EA, 2002, PUBLIC HEALTH NUTR, V5, P561, DOI 10.1079/PHN2001322
   Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703
   Tokunaga S, 2002, ANN EPIDEMIOL, V12, P157, DOI 10.1016/S1047-2797(01)00307-6
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Tsuda T, 2003, J NUTR, V133, P2125, DOI 10.1093/jn/133.7.2125
   Tsuda T, 2008, J AGR FOOD CHEM, V56, P642, DOI 10.1021/jf073113b
   VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E
   Wada K, 2005, INT J OBESITY, V29, P1093, DOI 10.1038/sj.ijo.0803012
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   World Health Organization (WHO), 2005, EURO1305 WHO, V12, P0
   Wu CH, 2003, OBES RES, V11, P1088, DOI 10.1038/oby.2003.149
   Wu CH, 2002, ARCH INTERN MED, V162, P1001, DOI 10.1001/archinte.162.9.1001
NR 63
TC 88
Z9 95
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV 1
PY 2008
VL 88
IS 5
BP 1341
EP 1352
DI 10.3945/ajcn.2008.26058
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 370OD
UT WOS:000260770600023
PM 18996871
DA 2025-04-28
ER

PT J
AU Franzini, L
   Ardigò, D
   Zavaroni, I
AF Franzini, Laura
   Ardigo, Diego
   Zavaroni, Ivana
TI Dietary antioxidants and glucose metabolism
SO CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
LA English
DT Article
DE antioxidant; diet; inflammation; insulin resistance; type 2 diabetes
ID coronary-heart-disease; conjugated linoleic-acid; insulin-resistance; oxidative stress; vitamin-e; cardiovascular-disease; vegetable intake; tocopherol supplementation; endothelial dysfunction; coffee consumption
AB Purpose of review Oxidative stress seems to play a pathogenic role in the vicious circle linking obesity, insulin resistance and type 2 diabetes. Hypothetically, dietary antioxidants should decrease oxidative stress and therefore improve glucose metabolism. However, many interventional trials evaluating the effect of antioxidant supplementation on insulin resistance, plasma glucose levels and risk of type 2 diabetes gave inconsistent results. Recent findings Many studies have recently demonstrated a positive effect of vitamin supplementation and of food enriched in antioxidants (seafood, whole nut, etc.) on markers of oxidative stress, insulin resistance, fasting plasma glucose and incidence of diabetes. The present paper critically reviews the consolidated notions on dietary antioxidants in view of the recent evidence. Summary Although a definitive estimation of the impact of dietary antioxidants on glucose metabolism is still lacking, food with high antioxidant concentrations seems to have a protective effect, improving oxidative stress-mediated detrimental effects on the vicious circle linking obesity, insulin resistance and redox imbalance.
C1 [Franzini, Laura; Ardigo, Diego; Zavaroni, Ivana] Univ Parma, Dept Internal Med & Biomed Sci, I-43100 Parma, Italy.
C3 University of Parma
RP Zavaroni, I (corresponding author), Via Gramsci 14, I-43100 Parma, Italy.
EM ivana.zavaroni@unipr.it
CR Antoniades C, 2003, HERZ, V28, P628, DOI 10.1007/s00059-003-2417-8
   Azadbakht L, 2007, DIABETES CARE, V30, P967, DOI 10.2337/dc06-2126
   Bose KSC, 2007, SMJ SINGAPORE MEDICAL JOURNAL, V48, P415
   Brownlee M, 2003, J CLIN INVEST, V112, P1788, DOI 10.1172/JCI200320501
   Bugianesi E, 2005, AM J GASTROENTEROL, V100, P1082, DOI 10.1111/j.1572-0241.2005.41583.x
   Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78
   Chen H, 2006, AM J PHYSIOL-HEART C, V290, PH137, DOI 10.1152/ajpheart.00768.2005
   Choi JS, 2007, BRIT J NUTR, V98, P264, DOI 10.1017/S000711450770497X
   Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
   Czernichow S, 2006, AM J CLIN NUTR, V84, P395
   Dauchet L, 2006, J NUTR, V136, P2588, DOI 10.1093/jn/136.10.2588
   De Caterina R, 2002, CIRCULATION, V106, P2543, DOI 10.1161/01.CIR.0000038500.43292.D7
   DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318
   Després JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Devaraj S, 2007, AM J CLIN NUTR, V86, P1392
   Esmaillzadeh A, 2006, AM J CLIN NUTR, V84, P1489, DOI 10.1093/ajcn/84.6.1489
   Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1
   Ford ES, 1999, AM J EPIDEMIOL, V149, P168, DOI 10.1093/oxfordjournals.aje.a009783
   Garg N, 2006, J PERIODONTAL RES, V41, P405, DOI 10.1111/j.1600-0765.2006.00889.x
   Gökkusu C, 2001, ENDOCR RES, V27, P377, DOI 10.1081/ERC-100106015
   Grassi D, 2005, AM J CLIN NUTR, V81, P611
   Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB
   Haber CA, 2003, AM J PHYSIOL-ENDOC M, V285, PE744, DOI 10.1152/ajpendo.00355.2002
   Hamer M, 2007, J HYPERTENS, V25, P2361, DOI 10.1097/HJH.0b013e3282efc214
   Hodge AM, 2007, AM J EPIDEMIOL, V165, P603, DOI 10.1093/aje/kwk061
   Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303
   Hozawa A, 2007, CLIN CHEM, V53, P447, DOI 10.1373/clinchem.2006.074930
   Inami S, 2007, INT HEART J, V48, P725, DOI 10.1536/ihj.48.725
   Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0
   KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035
   Korish AA, 2008, ARCH GERONTOL GERIAT, V46, P25, DOI 10.1016/j.archger.2007.02.006
   Kris-Etherton Penny M, 2002, AMERICAN JOURNAL OF MEDICINE, V113, P71S, DOI 10.1016/S0002-9343(01)00995-0
   Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803
   Li N, 2007, J NUTR, V137, P2717, DOI 10.1093/jn/137.12.2717
   Liu S, 2000, AM J CLIN NUTR, V72, P922
   Liu SM, 2004, DIABETES CARE, V27, P2993, DOI 10.2337/diacare.27.12.2993
   Manning PJ, 2004, DIABETES CARE, V27, P2166, DOI 10.2337/diacare.27.9.2166
   McSorley PT, 2005, DIABETIC MED, V22, P703, DOI 10.1111/j.1464-5491.2005.01506.x
   Montonen J, 2005, EUR J CLIN NUTR, V59, P441, DOI 10.1038/sj.ejcn.1602094
   Nakaya Y, 2000, AM J CLIN NUTR, V71, P54
   Parra D, 2007, EUR J NUTR, V46, P460
   Paynter NP, 2006, AM J EPIDEMIOL, V164, P1075, DOI 10.1093/aje/kwj323
   Reaven G, 2004, RECENT PROG HORM RES, V59, P207, DOI 10.1210/rp.59.1.207
   Reaven GM, 2005, ENDOCRIN METAB CLIN, V34, P49, DOI 10.1016/j.ecl.2004.12.001
   REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473
   Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447
   RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004
   Roberts CK, 2006, DIABETES RES CLIN PR, V73, P249, DOI 10.1016/j.diabres.2006.02.013
   SanchezLugo L, 1997, AM J CLIN NUTR, V66, P1224, DOI 10.1093/ajcn/66.5.1224
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   Sargeant LA, 2001, EUR J CLIN NUTR, V55, P342, DOI 10.1038/sj.ejcn.1601162
   Schulze MB, 2005, ANNU REV PUBL HEALTH, V26, P445, DOI 10.1146/annurev.publhealth.26.021304.144532
   Shih CK, 2008, BRIT J NUTR, V99, P59, DOI 10.1017/S0007114507781497
   Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446
   Song FF, 2007, CLIN SCI, V112, P599, DOI 10.1042/CS20060323
   Sugiura M, 2006, J EPIDEMIOL, V16, P71, DOI 10.2188/jea.16.71
   Syvertsen C, 2007, INT J OBESITY, V31, P1148, DOI 10.1038/sj.ijo.0803482
   Trevisan M, 2001, AM J EPIDEMIOL, V154, P348, DOI 10.1093/aje/154.4.348
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5
   Valtueña S, 2007, EUR J CLIN NUTR, V61, P69, DOI 10.1038/sj.ejcn.1602485
   Valtuena S, 2008, AM J CLIN NUTR, V87, P1290, DOI 10.1093/ajcn/87.5.1290
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Weinberg RB, 2001, ARTERIOSCL THROM VAS, V21, P1029, DOI 10.1161/01.ATV.21.6.1029
   Wu JHY, 2007, CLIN CHEM, V53, P511, DOI 10.1373/clinchem.2006.076992
   Xiao C, 2008, DIABETOLOGIA, V51, P139, DOI 10.1007/s00125-007-0859-x
   Ylönen K, 2003, AM J CLIN NUTR, V77, P1434
   Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302
   ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105
   Zhou JF, 2000, BIOMED ENVIRON SCI, V13, P44
NR 70
TC 34
Z9 37
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1363-1950
EI 1473-6519
J9 CURR OPIN CLIN NUTR
JI Curr. Opin. Clin. Nutr. Metab. Care
PD JUL 15
PY 2008
VL 11
IS 4
BP 471
EP 476
DI 10.1097/MCO.0b013e328303be79
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 354TR
UT WOS:000259662400018
PM 18542009
DA 2025-04-28
ER

PT J
AU Bortolotti, M
   Rudelle, S
   Schneiter, P
   Vidal, H
   Loizon, E
   Tappy, L
   Acheson, KJ
AF Bortolotti, Murielle
   Rudelle, Servane
   Schneiter, Philippe
   Vidal, Hubert
   Loizon, Emmanuelle
   Tappy, Luc
   Acheson, Kevin J.
TI Dairy calcium supplementation in overweight or obese persons: its effect on markers of fat metabolism
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID human adipose-tissue; dietary calcium; energy-expenditure; vitamin-d; intracellular calcium; organ distribution; lipid-metabolism; acid synthesis; body-weight; de-novo
AB Background: Dairy calcium supplementation has been proposed to increase fat oxidation and to inhibit lipogenesis. Objective: We aimed to investigate the effects of calcium supplementation on markers of fat metabolism. Design: In a placebo-controlled, crossover experiment, 10 overweight or obese subjects who were low calcium consumers received 800 mg dairy Ca/d for 5 wk. After 4 wk, adipose tissue was taken for biopsy for analysis of gene expression. Respiratory exchange, glycerol turnover, and subcutaneous adipose tissue microdialysis were performed for 7 h after consumption of 400 mg Ca or placebo, and the ingestion of either randomized slow-release caffeine (SRC; 300 mg) or lactose (500 mg). One week later, the test was repeated with the SRC or lactose crossover. Results: Calcium supplementation increased urinary calcium excretion by 16% (P = 0.017) but did not alter plasma parathyroid hormone or osteocalcin concentrations. Resting energy expenditure (59.9 +/- 3.0 or 59.6 +/- 3.3 kcal/ h), fat oxidation (58.4 +/- 2.5 or 53.8 +/- 2.2 mg/ min), plasma free fatty acid concentrations (0.63 +/- 0.02 or 0.62 +/- 0.03 mmol/ L), and glycerol turnover (3.63 +/- 0.41 or 3.70 +/- 0.38 mu mol . kg(-1) . min(-1)) were similar with or without calcium, respectively. SRC significantly increased free fatty acid concentrations, resting fat oxidation, and resting energy expenditure. During microdialysis, epinephrine increased dialysate glycerol concentrations by 250% without and 254% with calcium. Expression of 7 key metabolic genes in subcutaneous adipose tissue was not affected by calcium supplementation. Conclusion: Dairy calcium supplementation in overweight subjects with habitually low calcium intakes failed to alter fat metabolism and energy expenditure under resting conditions and during acute stimulation by caffeine or epinephrine.
C1 [Acheson, Kevin J.] Nestle Res Ctr, Dept Nutr & Hlth, CH-1000 Lausanne 26, Switzerland.
   [Bortolotti, Murielle; Rudelle, Servane; Schneiter, Philippe; Tappy, Luc] Univ Lausanne, Inst Physiol, Lausanne, Switzerland.
   [Vidal, Hubert; Loizon, Emmanuelle] Lyon Univ, INSERM, U870, Oullins, France.
   [Vidal, Hubert; Loizon, Emmanuelle] Lyon Univ, INRA, UMR 1235, Oullins, France.
C3 Nestle SA; Nestle Research Center; University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE
RP Acheson, KJ (corresponding author), Nestle Res Ctr, Dept Nutr & Hlth, CH-1000 Lausanne 26, Switzerland.
EM kevin.acheson@rdls.nestle.com
FU Nestec SA, Switzerland
CR Acheson KJ, 2004, AM J CLIN NUTR, V79, P40
   ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   ANGEL A, 1979, EUR J CLIN INVEST, V9, P355, DOI 10.1111/j.1365-2362.1979.tb00896.x
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   BARTER PJ, 1972, METABOLISM, V21, P117, DOI 10.1016/0026-0495(72)90063-7
   BJORNTORP P, 1978, METABOLISM, V27, P1853, DOI 10.1016/S0026-0495(78)80004-3
   Boon N, 2007, INT J OBESITY, V31, P1704, DOI 10.1038/sj.ijo.0803660
   Boon N, 2006, OBESITY, V14, P1739, DOI 10.1038/oby.2006.200
   Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999
   DENKE MA, 1993, J NUTR, V123, P1047
   DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315
   Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Guo ZK, 2000, INT J OBESITY, V24, P932, DOI 10.1038/sj.ijo.0801256
   Henry S, 1998, CLIN PHYSIOL, V18, P562
   HOFFMANN GE, 1980, BIOCHIM BIOPHYS ACTA, V620, P151, DOI 10.1016/0005-2760(80)90194-0
   Jacobsen R, 2005, INT J OBESITY, V29, P292, DOI 10.1038/sj.ijo.0802785
   Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, PE192, DOI 10.1152/ajpendo.1996.270.1.E192
   Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, PE379, DOI 10.1152/ajpendo.1997.272.3.E379
   Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558
   LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608
   LONNROTH P, 1987, AM J PHYSIOL, V253, PE228, DOI 10.1152/ajpendo.1987.253.2.E228
   Lorenzen JK, 2006, AM J CLIN NUTR, V83, P18
   Mathieu C, 2005, DIABETOLOGIA, V48, P1247, DOI 10.1007/s00125-005-1802-7
   Melanson EL, 2003, INT J OBESITY, V27, P196, DOI 10.1038/sj.ijo.802202
   Melanson EL, 2005, OBES RES, V13, P2102, DOI 10.1038/oby.2005.261
   MELLATI AM, 1970, METABOLIS, V19, P988, DOI 10.1016/0026-0495(70)90045-4
   *NAT LIB MED, 2008, DRUG INF CALC MEDL P, V0, P0
   Parikh SJ, 2004, J CLIN ENDOCR METAB, V89, P1196, DOI 10.1210/jc.2003-031398
   PATEL MS, 1975, METABOLISM, V24, P161, DOI 10.1016/0026-0495(75)90017-7
   Shahkhalili Y, 2001, AM J CLIN NUTR, V73, P246
   Shi H, 2001, FASEB J, V15, P291
   SJOSTROM L, 1973, ACTA MED SCAND, V194, P387
   WEISS L, 1986, BIOL CHEM H-S, V367, P905, DOI 10.1515/bchm3.1986.367.2.905
   WELBERG JWM, 1994, ANN NUTR METAB, V38, P185, DOI 10.1159/000177810
   Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690
   Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391
   Xue BZ, 2001, FASEB J, V15, P2527, DOI 10.1096/fj.01-0278fje
   Xue BZ, 1999, PHYSIOL GENOMICS, V1, P11, DOI 10.1152/physiolgenomics.1999.1.1.11
   Yanoff LB, 2006, CLIN ENDOCRINOL, V64, P523, DOI 10.1111/j.1365-2265.2006.02502.x
   Zemel MB, 2005, OBES RES, V13, P1218, DOI 10.1038/oby.2005.144
   Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132
   Zemel MB, 2005, INT J OBESITY, V29, P391, DOI 10.1038/sj.ijo.0802880
   Zemel MB, 2004, OBES RES, V12, P582, DOI 10.1038/oby.2004.67
   Zemel MB, 2001, J AM COLL NUTR, V20, P428S, DOI 10.1080/07315724.2001.10719180
   Zemel MB, 2002, J AM COLL NUTR, V21, P146S, DOI 10.1080/07315724.2002.10719212
NR 46
TC 31
Z9 37
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT 1
PY 2008
VL 88
IS 4
BP 877
EP 885
DI 10.1093/ajcn/88.4.877
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 358FX
UT WOS:000259903600003
PM 18842771
DA 2025-04-28
ER

PT J
AU Tanida, M
   Tsuruoka, N
   Shen, J
   Kiso, Y
   Nagai, K
AF Tanida, Mamoru
   Tsuruoka, Nobuo
   Shen, Jiao
   Kiso, Yoshinobu
   Nagai, Katsuya
TI Effects of oolong tea on renal sympathetic nerve activity and spontaneous hypertension in rats
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article
ID urethane-anesthetized rats; blood-pressure; brain histamine; vagal nerve; leptin; ghrelin; reflex; stimulation; responses; nucleus
AB In a previous study, evidence was presented that oolong tea (OT) reduced abdominal fat accumulation in diet-induced obese mice. In the study presented here, we examined the sympathetic and cardiovascular effects of intraduodenal injection of OT in urethane-anesthetized rats and found that it suppressed renal sympathetic nerve activity (RSNA) and blood pressure (BP). In addition, pretreatment with the histaminergic H3-receptor antagonist thioperamide or bilateral subdiaphragmatic vagotomy eliminated the effects of OT on RSNA and BP. Furthermore, OT drinking for 14 weeks reduced BP elevation in spontaneously hypertensive rats. These results thus suggest that OT may exert its hypotensive action through changes in autonomic neurotransmission via an afferent neural mechanism. Moreover, we found that intraduodenal injection of decaffeinated OT lowered RSNA and BP as well as OT, indicating that substances other than caffeine contained in OT may function as effective modulators of RSNA and BP. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Tanida, Mamoru; Shen, Jiao; Nagai, Katsuya] ANBAS Corp, Kita Ku, Osaka 5310072, Japan.
   [Tanida, Mamoru; Shen, Jiao; Nagai, Katsuya] Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan.
   [Kiso, Yoshinobu] Suntory Ltd, Inst Hlth Care Sci, Osaka 6180012, Japan.
C3 The University of Osaka; Suntory Holdings Ltd
RP Tanida, M (corresponding author), ANBAS Corp, Kita Ku, Osaka 5310072, Japan.
EM mtanida@anbas.co.jp
CR ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0
   Brown RE, 2001, PROG NEUROBIOL, V63, P637, DOI 10.1016/S0301-0082(00)00039-3
   Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   HANDA RK, 1985, J PHYSIOL-LONDON, V369, P311, DOI 10.1113/jphysiol.1985.sp015903
   Haynes WG, 2005, EXP PHYSIOL, V90, P683, DOI 10.1113/expphysiol.2005.031237
   Koda S, 2005, ENDOCRINOLOGY, V146, P2369, DOI 10.1210/en.2004-1266
   Lembo G, 2000, DIABETES, V49, P293, DOI 10.2337/diabetes.49.2.293
   Lin JK, 1998, J AGR FOOD CHEM, V46, P3635, DOI 10.1021/jf980223x
   Matsumura K, 2002, HYPERTENSION, V40, P694, DOI 10.1161/01.HYP.0000035395.51441.10
   Mutoh T, 2000, AM J PHYSIOL-REG I, V279, PR1215, DOI 10.1152/ajpregu.2000.279.4.R1215
   Nagai N, 1996, ENDOCRINOLOGY, V137, P504, DOI 10.1210/en.137.2.504
   Niijima A, 1998, J AUTONOM NERV SYST, V73, P19, DOI 10.1016/S0165-1838(98)00109-X
   NUMAO Y, 1975, JPN HEART J, V16, P719
   Osaka T, 2002, J PHYSIOL-LONDON, V540, P665, DOI 10.1113/jphysiol.2001.013475
   SAWCHENKO PE, 1981, SCIENCE, V214, P685, DOI 10.1126/science.7292008
   Tanida M, 2005, BRAIN RES, V1058, P44, DOI 10.1016/j.brainres.2005.07.048
   Tanida M, 2005, NEUROSCI LETT, V389, P109, DOI 10.1016/j.neulet.2005.07.036
   Tanida M, 2005, AM J PHYSIOL-REG I, V288, PR447, DOI 10.1152/ajpregu.00275.2004
   Tanida M, 2007, NEUROSCI LETT, V413, P88, DOI 10.1016/j.neulet.2006.11.035
   Yang MH, 2001, J NUTR BIOCHEM, V12, P14, DOI 10.1016/S0955-2863(00)00140-6
NR 21
TC 19
Z9 26
U1 0
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 
J9 METABOLISM
JI Metab.-Clin. Exp.
PD APR 15
PY 2008
VL 57
IS 4
BP 526
EP 534
DI 10.1016/j.metabol.2007.11.016
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 275VJ
UT WOS:000254099900015
PM 18328356
DA 2025-04-28
ER

PT J
AU Matsuyama, T
   Tanaka, Y
   Kamimaki, I
   Nagao, T
   Tokimitsu, I
AF Matsuyama, Takeshi
   Tanaka, Yuriko
   Kamimaki, Isamu
   Nagao, Tomonori
   Tokimitsu, Ichiro
TI Catechin safely improved higher levels of fatness, blood pressure, and cholesterol in children
SO OBESITY
LA English
DT Article
ID green tea; body-fat; energy-expenditure; metabolic syndrome; visceral fat; polyphenols; obesity; childhood; oxidation; caffeine
AB Objective: The purpose of this study was to evaluate the effects of a catechin-rich beverage on body fat and cardiovascular disease risk factors in obese children and to verify the safety of its use. Methods and Procedures: Obese or near-obese Japanese children were recruited for this study. A double-blind, randomized, controlled study was performed with a 4-week lead-in, a 24-week beverage ingestion period and a 12-week follow-up. Subjects ingested green tea containing 576 mg catechins ( catechin group) or 75 mg catechins ( control group) once per day for 24 weeks. Randomization was stratified by gender, age, and BMI. Subjects were instructed to maintain their usual lifestyles during the study period. Results: Data were analyzed using samples from 40 subjects ( catechin group; n = 21, control group; n = 19). There were no significant differences in major outcome variables, such as body fat mass, between the catechin and the control groups. When, however, the analysis was stratified using the median of the week-0 values, the decrease at week 24 in waist circumference, systolic blood pressure, and low-density lipoprotein cholesterol in the catechin group was significantly greater than that in the control group for the above-median category. Ingestion of the catechin-rich beverage was not associated with any adverse effects. Discussion: These findings suggest that ingestion of a catechin-rich beverage ameliorates serious obesity and cardiovascular disease risk factors without raising any safety concerns in Japanese children.
C1 [Nagao, Tomonori; Tokimitsu, Ichiro] Kao Corp, Hlth Care Food Res Labs, Sumida Ku, Tokyo, Japan.
   [Kamimaki, Isamu] Natl Hosp Org Saitama Natl Hosp, Dept Pediat, Wako, Saitama, Japan.
   [Matsuyama, Takeshi; Tanaka, Yuriko] Fussa Hosp, Dept Pediat, Tokyo, Japan.
C3 KAO Corporation
RP Nagao, T (corresponding author), Kao Corp, Hlth Care Food Res Labs, Sumida Ku, Tokyo, Japan.
EM nagao.tomonori@kao.co.jp
CR Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/bbrc.2000.2217
   Asayama K, 2002, INT J OBESITY, V26, P208, DOI 10.1038/sj.ijo.0801865
   Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094
   Chen W, 2005, DIABETES CARE, V28, P126, DOI 10.2337/diacare.28.1.126
   Cole TJ, 2008, BIOSTATISTICS, V9, P159, DOI 10.1093/biostatistics/kxm020
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Harada U, 2005, J HEALTH SCI, V51, P248, DOI 10.1248/jhs.51.248
   Huang TTK, 2001, OBES RES, V9, P283, DOI 10.1038/oby.2001.35
   ISHIWATARI N, 1990, CLIN ENDOCRINOL, V38, P601
   KIMIE Y, 1994, J JPN PEDIAT SOC, V98, P99
   Kitagawa T, 1998, CLIN PEDIATR, V37, P111, DOI 10.1177/000992289803700208
   Lin JK, 1998, J AGR FOOD CHEM, V46, P3635, DOI 10.1021/jf980223x
   Ma ZM, 1996, CLIN CHEM, V42, P942
   Matsushita Y, 2004, OBES RES, V12, P205, DOI 10.1038/oby.2004.27
   Matsuzawa Y, 2002, CIRC J, V66, P987, DOI 10.1253/circj.66.987
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   SOGABE M, 1995, J CLIN EXP MED, V173, P997
   Terasawa F, 1999, ZOO BIOL, V18, P153, DOI 10.1002/(SICI)1098-2361(1999)18:2<153::AID-ZOO7>3.0.CO;2-F
   TOKUNAGA K, 1983, INT J OBESITY, V7, P437
   Tonari Y, 2001, RINSHO BYORI, V49, P178
   Yoshinaga M, 2005, OBES RES, V13, P1135, DOI 10.1038/oby.2005.134
NR 23
TC 86
Z9 91
U1 2
U2 32
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
EI 
J9 OBESITY
JI Obesity
PD JUN 15
PY 2008
VL 16
IS 6
BP 1338
EP 1348
DI 10.1038/oby.2008.60
PG 11
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 307XU
UT WOS:000256353700027
PM 18356827
DA 2025-04-28
ER

PT J
AU Kelly, B
   Cretikos, M
   Rogers, K
   King, L
AF Kelly, Bridget
   Cretikos, Michelle
   Rogers, Kris
   King, Lesley
TI The commercial food landscape: outdoor food advertising around primary schools in Australia
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE public health; marketing; food; child; advertisements
ID television; children; alcohol; extent
AB Objective: Food marketing is linked to childhood obesity through its influence on children's food preferences, purchase requests and food consumption. We aimed to describe the volume and nature of outdoor food advertisements and factors associated with outdoor food advertising in the area surrounding Australian primary schools. Methods: Forty primary schools in Sydney and Wollongong were selected using random sampling within population density and socio-economic strata. The area within a 500m radius of each school was scanned and advertisements coded according to pre-defined criteria, including: food or non-food product advertisement, distance from the school, size and location. Food advertisements were further categorised as core foods, non-core foods and miscellaneous drinks (tea and coffee). Results: The number of advertisements identified was 9,151, of which 2,286 (25%) were for food. The number of non-core food advertisements was 1,834, this accounted for 80% of food advertisements. Soft drinks and alcoholic beverages were the food products most commonly advertised around primary schools (24% and 22% of food advertisements, respectively). Non-core food products were twice as likely to be advertised close to a primary school (95 non-core food advertisements per km(2) within 250 m vs. 46 advertisements per km(2) within 250-500 m). Conclusions: The density of non-core food advertisements within 500 m of primary schools, and the potential for repeated exposure of children to soft drink and alcoholic beverage advertisements in particular, highlights the need for outdoor food marketing policy intervention. Implications: Outdoor advertising is an important food marketing tool that should be considered in future debates on regulation of food marketing to children.
C1 [Kelly, Bridget; Cretikos, Michelle; Rogers, Kris; King, Lesley] Univ Sydney, Sch Publ Hlth, NSW Ctr Overweight & Obes, Sydney, NSW 2006, Australia.
   [Cretikos, Michelle] Ctr Epidemiol & Res, NSW Dept Hlth, Sydney, NSW, Australia.
C3 University of Sydney
RP Kelly, B (corresponding author), Univ Sydney, Sch Publ Hlth, NSW Ctr Overweight & Obes, Level 2 K25,Med Fdn Bldg, Sydney, NSW 2006, Australia.
EM Bridgetk@health.usyd.edu.au
CR Andrieu E, 2006, EUR J CLIN NUTR, V60, P434, DOI 10.1038/sj.ejcn.1602331
   Unknown -, 2004, JUNK FOOD GENERATION, V0, P0
   *ASUTR BUR STAT, 2006, HOUS EXP SURV 2003 2, V0, P0
   *AUST, 2004, RISK FACT MON RIS EP, V0, P0
   *AUSTR ASS NAT ADV, 2006, FOOD BEV ADV MARK CO, V0, P0
   *AUSTR BUR STAT, 2006, AUSTR SCH DIR, V0, P0
   Australian Bureau of Statistics, 2007, CENS POP HOUS SOC IN, V0, P0
   BOOTH ML, 2004, SCH PHYS ACTIVITY NU, V0, P2006
   Chapman K, 2006, HEALTH PROMOT INT, V21, P172, DOI 10.1093/heapro/dal021
   *CIT SYDN, 2005, CIT SYDN SIGN ADV ST, V0, P0
   *CONS INT, 2007, REC INT COD MARK FOO, V0, P0
   Dalmeny K, 2003, BROADCASTING BAD HEALTH: WHY FOOD ADVERTISING NEEDS TO BE CONTROLLED, V0, P0
   *DEP ED TRAIN, 2005, PUBL SCH NSW, V0, P0
   *DEP HLTH HUM SERV, 1996, EX SUMM REG RESTR SA, V0, P0
   *DEP LOC GOV, 2006, COMP INF NSW LOC GOV, V0, P0
   Department of Health and Ageing, 2001, AUSTR GUID HLTH EAT, V0, P0
   Hackbarth DP, 2001, PUBLIC HEALTH REP, V116, P558, DOI 10.1093/phr/116.6.558
   Hastings G, 2003, REV RES EFFECTS FOOD, V0, P0
   Kelly B, 2008, PUBLIC HEALTH NUTR, V11, P1180, DOI 10.1017/S1368980008001778
   Kelly B, 2007, PUBLIC HEALTH NUTR, V10, P1234, DOI 10.1017/S1368980007687126
   Kelly B, 2007, HEALTH PROMOT INT, V22, P284, DOI 10.1093/heapro/dam026
   LUKE D, 2000, TOB CONTROL, V16, P23
   McGinnis MJ, 2006, FOOD MARKETING CHILD, V0, P0, DOI DOI 10.17226/11514
   Neville L, 2005, HEALTH PROMOT INT, V20, P105, DOI 10.1093/heapro/dah601
   *NSW GOV DEP PLANN, 2007, TRANSP CORR OUTD ADV, V0, P0
   Pasch KE, 2007, J STUD ALCOHOL DRUGS, V68, P587, DOI 10.15288/jsad.2007.68.587
   Pucci LG, 1998, AM J PREV MED, V15, P155, DOI 10.1016/S0749-3797(98)00034-8
   Schor JB, 2007, J LAW MED ETHICS, V35, P10, DOI 10.1111/j.1748-720X.2007.00110.x
   Thorburn AW, 2005, OBES REV, V6, P187, DOI 10.1111/j.1467-789X.2005.00187.x
   WACHTLER S, 2007, BOSTON YOUTH SPEAK C, V0, P0
NR 31
TC 77
Z9 82
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1326-0200
EI 1753-6405
J9 AUST NZ J PUBL HEAL
JI Aust. N. Z. Publ. Health
PD DEC 15
PY 2008
VL 32
IS 6
BP 522
EP 528
DI 10.1111/j.1753-6405.2008.00303.x
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 382WP
UT WOS:000261636400006
PM 19076742
DA 2025-04-28
ER

PT J
AU Mika, M
   Wikiera, A
   Zyla, K
AF Mika, Magdalena
   Wikiera, Agnieszka
   Zyla, Krzysztof
TI Effects of non-fermented tea extracts on in vitro digestive hydrolysis of lipids and on cholesterol precipitation
SO EUROPEAN FOOD RESEARCH AND TECHNOLOGY
LA English
DT Article
DE green tea; cholesterol; lipids; in vitro digestibility; catechin gallates
ID diet-induced obesity; green tea; epigallocatechin gallate; catechin-polyphenols; invitro method; fat oxidation; rats; absorption; caffeine; acid
AB Extracts of non-fermented teas precipitated cholesterol and decreased dialysability of lipids in an in vitro model that simulated digestion in humans. The efficiency of tea extracts was affected by catechins and mainly by EGCG, ECG, GCG and CG. Total amounts and concentrations of individual catechins in extracts depended strongly on the tea brands. There were significant relationships between amounts of dialysable products of triglyceride hydrolysis, amounts of precipitated cholesterol, and concentrations of individual catechin gallates in tea brews. Dialysability of lipids was effectively reduced by tea extracts high in GCG and CG. Dialysability of lipids was strongly correlated with the sum of GCG and CG (R-2=84.64%) whereas precipitation of cholesterol was highly correlated with total amounts of catechin gallates in the tea extracts (R-2=89.59%).
C1 [Mika, Magdalena; Wikiera, Agnieszka; Zyla, Krzysztof] Agr Univ Krakow, Fac Food Technol, Dept Food Biotechnol, PL-31149 Krakow, Poland.
C3 University of Agriculture in Krakow
RP Mika, M (corresponding author), Agr Univ Krakow, Fac Food Technol, Dept Food Biotechnol, Ul 122 Balicka, PL-31149 Krakow, Poland.
EM mmika@ar.krakow.pl
CR ALLAIN CC, 1974, CLIN CHEM, V20, P475
   Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   FOSSATI P, 1982, CLIN CHEM, V28, P2077
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Ikeda I, 2003, J AGR FOOD CHEM, V51, P7303, DOI 10.1021/jf034728l
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Kajimoto O, 2005, J HEALTH SCI, V51, P161, DOI 10.1248/jhs.51.161
   Khokhar S, 2002, J AGR FOOD CHEM, V50, P565, DOI 10.1021/jf010153l
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kobayashi M, 2005, BIOSCI BIOTECH BIOCH, V69, P2455, DOI 10.1271/bbb.69.2455
   Lin JK, 1998, J AGR FOOD CHEM, V46, P3635, DOI 10.1021/jf980223x
   Lin YL, 1996, J AGR FOOD CHEM, V44, P1387, DOI 10.1021/jf950652k
   Löest HB, 2002, J NUTR, V132, P1282, DOI 10.1093/jn/132.6.1282
   MILLER DD, 1981, AM J CLIN NUTR, V34, P2248, DOI 10.1093/ajcn/34.10.2248
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nakamura Y, 2001, J HEALTH SCI, V47, P107, DOI 10.1248/jhs.47.107
   Peterson J, 2005, J FOOD COMPOS ANAL, V18, P487, DOI 10.1016/j.jfca.2004.05.006
   WIERZEJEWSKA R, 2004, ZYWIENIE CZLOWIEKA M, V3, P274
   Witkowska A, 2003, BROMATOLOGIA CHEM S, V0, P401
   WOLTERS MGE, 1993, BRIT J NUTR, V69, P849, DOI 10.1079/BJN19930085
   Yang TTC, 1997, PHARMACOL RES, V35, P505, DOI 10.1006/phrs.1997.0176
   ZYLA K, 1995, BRIT J NUTR, V74, P3, DOI 10.1079/BJN19950102
NR 26
TC 6
Z9 6
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1438-2377
EI 
J9 EUR FOOD RES TECHNOL
JI Eur. Food Res. Technol.
PD FEB 15
PY 2008
VL 226
IS 4
BP 731
EP 736
DI 10.1007/s00217-007-0584-1
PG 6
WC Food Science & Technology
SC Food Science & Technology
GA 253TH
UT WOS:000252540000012
DA 2025-04-28
ER

PT J
AU Hamada, T
   Kotani, K
   Higashi, A
   Ikeda, J
   Tagaki, E
   Igarashi, A
   Matsubara, C
   Yoshida, T
   Sakane, N
AF Hamada, Taku
   Kotani, Kazuhiko
   Higashi, Akane
   Ikeda, Junko
   Tagaki, Emi
   Igarashi, Aiko
   Matsubara, Chikanobu
   Yoshida, Toshihide
   Sakane, Naoki
TI Lack of association of the Trp64Arg polymorphism of β3-adrenergic receptor gene with energy expenditure in response to caffeine among young healthy women
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE beta(3)-adrenergic receptor; polymorphism; caffeine; energy expenditure; genotype
ID basal metabolic-rate; insulin-resistance syndrome; obese finns; weight-loss; mutation; fat; japanese
AB A close relationship between coffee intake and certain metabolic disorders is known. Caffeine, one of coffee components, can increase energy expenditure (EE), but there are considerable individual differences in the caffeine effects on EE, and the causes have not been fully established in humans. The Arg allele in the beta(3)-adrenergic receptor gene (beta(3)-AR), a marker for obesity-related traits, may be a contributor to individual variations in EE. This study investigated the effect of the Arg allele of beta(3)-AR on caffeine-induced increases in EE. In 44 healthy young women (21 +/- 1 years), physical characteristics, blood pressure, biochemical profiles and dietary nutritional intake were measured. A caffeine-loading test was conducted at a dosage of 4 mg per body weight (kg). EE was measured using an indirect open-circuit calorimeter for a 10-min period before, and at 30 min and 60 min after the caffeine-loading test. The beta(3)-AR Trp64Arg polymorphism was detected with a PCR-restriction fragment length polymorphism method. The frequency of the Arg allele was 24%. The distribution of the Trp/Trp, Trp/Arg, and Arg/Arg genotypes was 58%, 36%, and 6%, respectively. At the baseline, subjects with the Arg/Arg genotype had a significantly lower EE level than those with the Trp/Trp or Trp/Arg genotype. After the caffeine-loading test, there were caffeine-induced increases in EE in all genotypes, but there were no differences in the levels of increase among the genotypes. These findings suggest that the genotypes of beta(3)-AR Trp64Arg polymorphism might be not associated with caffeine-induced increases in EE levels.
C1 [Hamada, Taku; Kotani, Kazuhiko; Sakane, Naoki] Natl Hosp Org Kyoto Med Ctr, Clin Res Inst Endocrine & Metab Dis, Div Med & Diabet Educ, Fushimi Ku, Kyoto 6128555, Japan.
   [Kotani, Kazuhiko] Tottori Univ, Fac Med, Div Hlth Adm & Promot, Yonago, Tottori 683, Japan.
   [Higashi, Akane; Tagaki, Emi; Igarashi, Aiko; Matsubara, Chikanobu] Kyoto Prefectural Univ, Fac Human Environm, Kyoto 606, Japan.
   [Ikeda, Junko] Kyoto Bunkyo Jr Coll, Dept Home Econ, Tokyo, Japan.
   [Yoshida, Toshihide] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Diabet Endocrinol & Metab, Kyoto, Japan.
C3 Tottori University; Kyoto Prefectural University; Kyoto Prefectural University of Medicine
RP Sakane, N (corresponding author), Natl Hosp Org Kyoto Med Ctr, Clin Res Inst Endocrine & Metab Dis, Div Med & Diabet Educ, Fushimi Ku, 1-1 Mukaihata Cho, Kyoto 6128555, Japan.
EM nsakane@kyotolan.hosp.go.jp
CR BUKOWIECKI LJ, 1983, AM J PHYSIOL, V244, PR500, DOI 10.1152/ajpregu.1983.244.4.R500
   CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605
   Date C, 1996, J EPIDEMIOL, V6, P0
   KADOWAKI H, 1995, BIOCHEM BIOPH RES CO, V215, P555, DOI 10.1006/bbrc.1995.2500
   Kurokawa N, 2001, OBES RES, V9, P741, DOI 10.1038/oby.2001.102
   Lusk G, 1924, J BIOL CHEM, V59, P41
   PietriRouxel F, 1997, EUR J BIOCHEM, V247, P1174, DOI 10.1111/j.1432-1033.1997.01174.x
   Sakane N, 1997, DIABETES, V46, P1633, DOI 10.2337/diabetes.46.10.1633
   Sakane N, 1997, DIABETES CARE, V20, P1887, DOI 10.2337/diacare.20.12.1887
   Sakane N, 1997, DIABETOLOGIA, V40, P200, DOI 10.1007/s001250050663
   Sipilainen R, 1997, DIABETES, V46, P77, DOI 10.2337/diabetes.46.1.77
   Tchernof A, 1999, DIABETES, V48, P1425, DOI 10.2337/diabetes.48.7.1425
   Umekawa T, 1999, DIABETES, V48, P117, DOI 10.2337/diabetes.48.1.117
   Valve R, 1998, DIABETOLOGIA, V41, P357, DOI 10.1007/s001250050915
   WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603
   WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604
   YOSHIDA T, 1994, INT J OBESITY, V18, P345
   YOSHIDA T, 1995, LANCET, V346, P1433, DOI 10.1016/S0140-6736(95)92452-3
   YOSHIOKA K, 1990, J NUTR SCI VITAMINOL, V36, P173, DOI 10.3177/jnsv.36.173
NR 19
TC 4
Z9 5
U1 0
U2 1
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD APR 15
PY 2008
VL 214
IS 4
BP 365
EP 370
DI 10.1620/tjem.214.365
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 296ZN
UT WOS:000255584600011
PM 18441513
DA 2025-04-28
ER

PT J
AU Wigle, DT
   Turner, MC
   Gomes, J
   Parent, ME
AF Wigle, Donald T.
   Turner, Michelle C.
   Gomes, James
   Parent, Marie-Elise
TI Role of hormonal and other factors in human prostate cancer
SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS
LA English
DT Review
ID receptor gene polymorphisms; occupational risk-factors; endogenous sex-hormones; body-mass index; growth-factor-i; excision-repair capacity; meta-regression analysis; large prospective cohort; retinol efficacy trial; igf binding protein-3
AB American men have a lifetime risk of about 18% for prostate cancer diagnosis. Large international variations in prostate cancer risks and increased risks among migrants from low- to high-risk countries indicate important roles for environmental factors. Major known risk factors include age, family history, and country/ethnicity. Type 2 diabetes appears to reduce risk, while high birth weight and adult height are linked to increased risk of aggressive prostate cancer. Limited evidence supports an association with a history of sexually transmitted infections. A previous meta-analysis of eight cohort studies indicated no associations with plasma androgen, estrogen, or sex hormone binding globulin (SHBG) levels. However, there were dose-response relationships with baseline plasma testosterone levels in two studies that adjusted for other serum hormones and obesity. Finasteride (a drug that blocks testosterone activation) reduced prostate cancer risk by 25%. Low-frequency genes linked to familial prostate cancer only explain a small fraction of all cases. Sporadic cases were linked to relatively common polymorphisms of genes involved in (1) androgen synthesis, activation, inactivation and excretion, (2) hormone and vitamin D receptors, (3) carcinogen metabolism, and (4) DNA repair. Epidemiologic evidence supports protective roles for dietary selenium, vitamin E, pulses, tomatoes/lycopene, and soy foods, and high plasma 1,25-diliydroxyvitamin D levels. There is inadequate evidence that vegetables, fruit, carotenoids, and vitamins A and C reduce risk and that animal fat, alpha-linoleic acid, meat, coffee, and tea increase risk. Two major cohort studies found dose-response relationships with dietary calcium intake. Total dietary energy intake may enhance risk. Limited evidence supports a protective role for physical activity and elevated risk for farmers and other men with occupational pesticide exposure, particularly to organochlorine compounds and phenoxy herbicides. There is inadequate evidence for a relationship with alcohol or smoking. Most known or suspected external risk factors may act through hormonal mechanisms, but our review found little supporting evidence, and substantial further research is needed.
C1 [Wigle, Donald T.; Turner, Michelle C.] Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada.
   [Gomes, James] Univ Ottawa, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada.
   [Parent, Marie-Elise] Univ Quebec, INRS Inst Armand Frappier, Laval, PQ, Canada.
C3 University of Ottawa; University of Ottawa; University of Quebec; Institut national de la recherche scientifique (INRS)
RP Wigle, DT (corresponding author), Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Room 318B,1 Stewart St, Ottawa, ON K1N 6N5, Canada.
EM don.wigle@sympatico.ca
CR Adami HO, 2003, CANCER EPIDEM BIOMAR, V12, P872
   Agalliu I, 2006, PROSTATE, V66, P146, DOI 10.1002/pros.20305
   Ahonen MH, 2000, CANCER CAUSE CONTROL, V11, P847, DOI 10.1023/A:1008923802001
   Alavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040
   Alavanja MCR, 2005, SCAND J WORK ENV HEA, V31, P39
   *AM CANC SOC, 2006, CANC FACTS FIG 2006, V0, P0
   Antognelli C, 2005, PROSTATE, V63, P240, DOI 10.1002/pros.20184
   Aronson KJ, 1996, AM J EPIDEMIOL, V143, P363
   Astorg P, 2004, CANCER CAUSE CONTROL, V15, P367, DOI 10.1023/B:CACO.0000027498.94238.a3
   Baglietto L, 2006, INT J CANCER, V119, P1501, DOI 10.1002/ijc.21983
   Ballard T, 2000, AVIAT SPACE ENVIR MD, V71, P216
   BARRETTCONNOR E, 1990, CANCER RES, V50, P169
   Bernal-Delgado E, 1998, FERTIL STERIL, V70, P191, DOI 10.1016/S0015-0282(98)00142-3
   Berndt SI, 2006, J UROLOGY, V175, P1613, DOI 10.1016/S0022-5347(05)00958-4
   Berndt SI, 2005, NUTRITION, V21, P686, DOI 10.1016/j.nut.2004.11.012
   Binnie MC, 2005, PROSTATE, V63, P309, DOI 10.1002/pros.20178
   Bonovas S, 2004, DIABETOLOGIA, V47, P1071, DOI 10.1007/s00125-004-1415-6
   Bosland M C, 2000, J NATL CANCER INST MONOGR, V0, P39
   BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P235, DOI 10.1007/BF00051795
   Brouwer IA, 2004, J NUTR, V134, P919, DOI 10.1093/jn/134.4.919
   Bruner DW, 2003, INT J CANCER, V107, P797, DOI 10.1002/ijc.11466
   BRUSICK D, 1986, MUTAT RES, V169, P105, DOI 10.1016/0165-1218(86)90089-3
   Buxton JA, 1999, AM J IND MED, V35, P82, DOI 10.1002/(SICI)1097-0274(199901)35:1<82::AID-AJIM11>3.0.CO;2-E
   Cáceres DD, 2005, EUR J EPIDEMIOL, V20, P79, DOI 10.1007/s10654-004-1632-9
   Chan JM, 2001, AM J CLIN NUTR, V74, P549
   Chang BL, 2002, CANCER RES, V62, P1784
   Charles LE, 2003, AM J EPIDEMIOL, V157, P683, DOI 10.1093/aje/kwg044
   Chen C, 2003, CANCER EPIDEM BIOMAR, V12, P1410
   Chu KC, 2003, CANCER-AM CANCER SOC, V97, P1507, DOI 10.1002/cncr.11212
   Cicek MS, 2004, PROSTATE, V59, P69, DOI 10.1002/pros.10358
   COMSTOCK GW, 1993, CANCER EPIDEM BIOMAR, V2, P219
   Costa I, 2005, PROSTATE, V64, P246, DOI 10.1002/pros.20241
   Culig Z, 2000, UROL RES, V28, P211, DOI 10.1007/s002400000111
   Dagnelie PC, 2004, BJU INT, V93, P1139, DOI 10.1111/j.1464-410X.2004.04795.x
   Dennis LK, 2002, PROSTATE CANCER P D, V5, P193, DOI 10.1038/sj.pcan.4500586
   Dennis LK, 2002, EPIDEMIOLOGY, V13, P72, DOI 10.1097/00001648-200201000-00012
   Dennis LK, 2000, PROSTATE, V42, P56
   Dillner J, 1998, INT J CANCER, V75, P564, DOI 10.1002/(SICI)1097-0215(19980209)75:4<564::AID-IJC12>3.0.CO;2-9
   Ding EL, 2006, JAMA-J AM MED ASSOC, V295, P1288, DOI 10.1001/jama.295.11.1288
   Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094
   DONN AS, 1985, B CANCER, V72, P381
   Dorgan JP, 1998, CANCER EPIDEM BIOMAR, V7, P1069
   Douglas JA, 2005, CANCER EPIDEM BIOMAR, V14, P2035, DOI 10.1158/1055-9965.EPI-05-0170
   Eaton NE, 1999, BRIT J CANCER, V80, P930, DOI 10.1038/sj.bjc.6690445
   Ellem S J, 2006, MINERVA ENDOCRINOL, V31, P1
   Ellison LF, 2000, EUR J CANCER PREV, V9, P125, DOI 10.1097/00008469-200004000-00009
   Engeland A, 2003, BRIT J CANCER, V89, P1237, DOI 10.1038/sj.bjc.6601206
   Enokida H, 2006, CANCER-AM CANCER SOC, V106, P79, DOI 10.1002/cncr.21577
   Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081
   Etminan M, 2005, CANCER CAUSE CONTROL, V16, P1125, DOI 10.1007/s10552-005-0334-2
   Etminan M, 2004, CANCER EPIDEM BIOMAR, V13, P340
   Farnham JM, 2005, HUM GENET, V116, P179, DOI 10.1007/s00439-004-1220-9
   Friedenreich CM, 2002, J NUTR, V132, P3456S, DOI 10.1093/jn/132.11.3456S
   Fukatsu T, 2004, ANTICANCER RES, V24, P2431
   Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118
   Gao X, 2005, JNCI-J NATL CANCER I, V97, P1768, DOI 10.1093/jnci/dji402
   Gayther SA, 2000, CANCER RES, V60, P4513
   Giles GG, 2001, ANN ONCOL, V12, P761, DOI 10.1023/A:1011131105617
   Giovannucci E, 2006, CANCER EPIDEM BIOMAR, V15, P203, DOI 10.1158/1055-9965.EPI-05-0586
   Giovannucci E, 2004, INT J EPIDEMIOL, V33, P217, DOI 10.1093/ije/dyh020
   Giovannucci EL, 2005, ARCH INTERN MED, V165, P1005, DOI 10.1001/archinte.165.9.1005
   Goldacre MJ, 2005, FERTIL STERIL, V84, P1438, DOI 10.1016/j.fertnstert.2005.04.052
   Gonzalez CA, 2006, PUBLIC HEALTH NUTR, V9, P124, DOI 10.1079/PHN2005934
   Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050
   Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J
   Gsur A, 2004, WORLD J UROL, V21, P414, DOI 10.1007/s00345-003-0378-4
   Guess HA, 1997, CANCER EPIDEM BIOMAR, V6, P21
   Gun RT, 2006, OCCUP ENVIRON MED, V63, P476, DOI 10.1136/oem.2005.023796
   Härkönen PL, 2004, J STEROID BIOCHEM, V92, P297, DOI 10.1016/j.jsbmb.2004.10.016
   Hayes RB, 1999, CANCER EPIDEM BIOMAR, V8, P25
   Hedelin M, 2006, CANCER CAUSE CONTROL, V17, P169, DOI 10.1007/s10552-005-0342-2
   Heikkilä R, 1999, CANCER, V86, P312, DOI 10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.3.CO;2-Z
   HEILBRUN LK, 1986, BRIT J CANCER, V54, P677, DOI 10.1038/bjc.1986.226
   Hemminki K, 2002, CANCER EPIDEM BIOMAR, V11, P1638
   Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427
   Hickey K, 2001, EPIDEMIOL REV, V23, P115, DOI 10.1093/oxfordjournals.epirev.a000776
   Hirayama T, 1979, NATL CANCER INST MONOGR, V0, P149
   Ho GYF, 2003, BRIT J CANCER, V88, P263, DOI 10.1038/sj.bjc.6600747
   Hodge AM, 2004, CANCER CAUSE CONTROL, V15, P11, DOI 10.1023/B:CACO.0000016568.25127.10
   Hsing AW, 2001, JNCI-J NATL CANCER I, V93, P783, DOI 10.1093/jnci/93.10.783
   Hsing AW, 2002, J NATL CANCER I, V94, P1648, DOI 10.1093/jnci/94.21.1648
   Hsing AW, 2002, CANCER EPIDEM BIOMAR, V11, P337
   HSING AW, 1993, CANCER EPIDEM BIOMAR, V2, P27
   Hsing AW, 2000, CANCER EPIDEM BIOMAR, V9, P1335
   Hu JJ, 2004, CANCER RES, V64, P1197, DOI 10.1158/0008-5472.CAN-03-2670
   Huang HY, 2003, AM J EPIDEMIOL, V157, P335, DOI 10.1093/aje/kwf210
   Huang LW, 2004, J ANDROL, V25, P330
   Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807
   Hubbard JS, 2004, UROLOGY, V63, P253, DOI 10.1016/j.urology.2003.09.060
   *INT AG RES CANC, 2005, GLOB 2002 CANC INC M, V0, P0
   *INT AG RES CANC, 1994, BER CADM MERC EXP GL, V0, P0
   Jacobs ET, 2004, J STEROID BIOCHEM, V89-90, P533, DOI 10.1016/j.jsbmb.2004.03.063
   Jain MG, 1998, INT J CANCER, V78, P707, DOI 10.1002/(SICI)1097-0215(19981209)78:6<707::AID-IJC7>3.0.CO;2-2
   Janssen JAMJL, 2004, J CLIN ENDOCR METAB, V89, P4391, DOI 10.1210/jc.2004-0232
   Ji Q, 2005, MOL CELL ENDOCRINOL, V229, P103, DOI 10.1016/j.mce.2004.08.012
   Jian L, 2005, INT J CANCER, V113, P1010, DOI 10.1002/ijc.20667
   Jian L, 2004, INT J CANCER, V108, P130, DOI 10.1002/ijc.11550
   John EM, 2005, CANCER RES, V65, P5470, DOI 10.1158/0008-5472.CAN-04-3134
   Johns LE, 2003, BJU INT, V91, P789, DOI 10.1046/j.1464-410X.2003.04232.x
   Kasper JS, 2006, CANCER EPIDEM BIOMAR, V15, P2056, DOI 10.1158/1055-9965.EPI-06-0410
   Keshava C, 2004, AM J EPIDEMIOL, V160, P825, DOI 10.1093/aje/kwh294
   King IB, 2005, CANCER EPIDEM BIOMAR, V14, P988, DOI 10.1158/1055-9965.EPI-04-0517
   Kolonel LN, 1996, CANCER CAUSE CONTROL, V7, P83, DOI 10.1007/BF00115640
   Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795
   Korodi Z, 2005, CANCER EPIDEM BIOMAR, V14, P2952, DOI 10.1158/1055-9965.EPI-05-0602
   Kraft P, 2005, PLOS GENET, V1, P603, DOI 10.1371/journal.pgen.0010068
   Krstev S, 1998, AM J IND MED, V34, P421, DOI 10.1002/(SICI)1097-0274(199811)34:5<421::AID-AJIM2>3.0.CO;2-T
   Krüger S, 2005, LANCET ONCOL, V6, P566, DOI 10.1016/S1470-2045(05)70253-9
   Kumazawa T, 2004, INT J CANCER, V110, P140, DOI 10.1002/ijc.20070
   Lau KM, 2000, CANCER RES, V60, P3175
   LE ML, 1994, EPIDEMIOLOGY, V5, P276
   Leitzmann MF, 2004, AM J CLIN NUTR, V80, P204
   Li LC, 2004, BIOCHEM BIOPH RES CO, V321, P455, DOI 10.1016/j.bbrc.2004.06.164
   Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8
   Li SF, 2003, ANN NY ACAD SCI, V983, P161, DOI 10.1111/j.1749-6632.2003.tb05971.x
   Low YL, 2005, J NUTR, V135, P2680, DOI 10.1093/jn/135.11.2680
   Lynge E, 2002, J UROLOGY, V168, P488, DOI 10.1016/S0022-5347(05)64664-2
   MacInnis RJ, 2003, CANCER EPIDEM BIOMAR, V12, P1417
   MacInnis RJ, 2006, CANCER CAUSE CONTROL, V17, P989, DOI 10.1007/s10552-006-0049-z
   MacLean CH, 2006, JAMA-J AM MED ASSOC, V295, P403, DOI 10.1001/jama.295.4.403
   Malila N, 2006, EUR J CANCER PREV, V15, P103, DOI 10.1097/01.cej.0000197448.49239.60
   Marchesani M, 2003, JNCI-J NATL CANCER I, V95, P812, DOI 10.1093/jnci/95.11.812
   Mononen N, 2006, CANCER RES, V66, P743, DOI 10.1158/0008-5472.CAN-05-1723
   Mori T, 1996, JPN J CANCER RES, V87, P570, DOI 10.1111/j.1349-7006.1996.tb00261.x
   Muir KR, 2005, SCAND J WORK ENV HEA, V31, P55
   Murata M, 2001, CANCER LETT, V165, P171, DOI 10.1016/S0304-3835(01)00398-6
   Nam RK, 2003, CANCER EPIDEM BIOMAR, V12, P1429
   Negri E, 2005, INT J CANCER, V114, P648, DOI 10.1002/ijc.20755
   Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x
   Neuhausen SL, 2005, PROSTATE, V64, P168, DOI 10.1002/pros.20216
   Nilsen TIL, 2005, INT J CANCER, V113, P1002, DOI 10.1002/ijc.20674
   Nock NL, 2006, CANCER EPIDEM BIOMAR, V15, P756, DOI 10.1158/1055-9965.EPI-05-0826
   Nock NL, 2006, CARCINOGENESIS, V27, P1842, DOI 10.1093/carcin/bgl022
   Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A
   Nomura AM, 2001, EPIDEMIOL REV, V23, P126, DOI 10.1093/oxfordjournals.epirev.a000777
   Nomura AMY, 1996, CANCER EPIDEM BIOMAR, V5, P621
   Nomura AMY, 1998, CANCER CAUSE CONTROL, V9, P425, DOI 10.1023/A:1008875819232
   Nomura AMY, 1997, CANCER EPIDEM BIOMAR, V6, P487
   Noonan-Wheeler FC, 2006, PROSTATE, V66, P49, DOI 10.1002/pros.20320
   Ntais C, 2003, CANCER EPIDEM BIOMAR, V12, P1395
   Ntais C, 2005, CANCER EPIDEM BIOMAR, V14, P176
   Ntais C, 2003, CANCER EPIDEM BIOMAR, V12, P120
   Ogishima T, 2005, CLIN CANCER RES, V11, P1028
   Parent MÉ, 2001, EPIDEMIOL REV, V23, P138, DOI 10.1093/oxfordjournals.epirev.a000779
   Patel AV, 2005, CANCER EPIDEM BIOMAR, V14, P275
   PEEHL DM, 1986, IN VITRO CELL DEV B, V22, P82
   Plaskon LA, 2003, CANCER EPIDEM BIOMAR, V12, P604
   Platz EA, 2004, CANCER CAUSE CONTROL, V15, P255, DOI 10.1023/B:CACO.0000024245.24880.8a
   Platz EA, 2004, AM J EPIDEMIOL, V159, P444, DOI 10.1093/aje/kwh062
   Platz EA, 2003, CANCER RES, V63, P8542
   Platz EA, 1998, AM J EPIDEMIOL, V147, P1140
   Platz EA, 2002, J NUTR, V132, P3471S, DOI 10.1093/jn/132.11.3471S
   Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619
   POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548
   Pukkala E, 2002, BRIT MED J, V325, P567, DOI 10.1136/bmj.325.7364.567
   Quiñones LA, 2006, ASIAN J ANDROL, V8, P349, DOI 10.1111/j.1745-7262.2006.00135.x
   REICHMAN ME, 1990, CANCER RES, V50, P2311
   Ren CZ, 2004, CANCER RES, V64, P969, DOI 10.1158/0008-5472.CAN-03-2592
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3
   Reynolds P, 1999, AM J IND MED, V36, P271, DOI 10.1002/(SICI)1097-0274(199908)36:2<271::AID-AJIM6>3.3.CO;2-9
   Rhodes DR, 2002, CANCER RES, V62, P4427
   Ritchey JD, 2005, CANCER EPIDEM BIOMAR, V14, P1703, DOI 10.1158/1055-9965.EPI-04-0809
   Rodriguez C, 2005, AM J EPIDEMIOL, V161, P147, DOI 10.1093/aje/kwh334
   Rodriguez C, 2001, CANCER EPIDEM BIOMAR, V10, P345
   Rodriguez C, 2004, CANCER EPIDEM BIOMAR, V13, P378
   Rohrmann S, 2005, CANCER CAUSE CONTROL, V16, P1189, DOI 10.1007/s10552-005-0304-8
   Rovito PM, 2005, PROSTATE CANCER P D, V8, P69, DOI 10.1038/sj.pcan.4500780
   Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881
   Rusiecki JA, 2006, INT J CANCER, V118, P3118, DOI 10.1002/ijc.21758
   Rusiecki JA, 2004, JNCI-J NATL CANCER I, V96, P1375, DOI 10.1093/jnci/djh264
   Salam MT, 2005, UROL ONCOL-SEMIN ORI, V23, P246, DOI 10.1016/j.urolonc.2004.12.014
   Schaid DJ, 2004, HUM MOL GENET, V13, PR103, DOI 10.1093/hmg/ddh072
   Schuurman AG, 1999, BRIT J CANCER, V80, P1107, DOI 10.1038/sj.bjc.6690472
   Schuurman AG, 2002, CANCER CAUSE CONTROL, V13, P573, DOI 10.1023/A:1016332208339
   Schuurman AG, 1999, CANCER CAUSE CONTROL, V10, P597, DOI 10.1023/A:1008925103542
   Sesso HD, 2001, INT J EPIDEMIOL, V30, P749, DOI 10.1093/ije/30.4.749
   Severi G, 2006, CANCER EPIDEM BIOMAR, V15, P86, DOI 10.1158/1055-9965.EPI-05-0633
   Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847
   Sharma-Wagner S, 2000, J OCCUP ENVIRON MED, V42, P517, DOI 10.1097/00043764-200005000-00010
   Sharpe CR, 2002, EUR J CANCER PREV, V11, P497, DOI 10.1097/00008469-200210000-00013
   Sharpe CR, 2001, EPIDEMIOLOGY, V12, P546, DOI 10.1097/00001648-200109000-00014
   Sharpe RM, 1998, ENVIRON HEALTH PERSP, V106, PA220, DOI 10.2307/3433998
   Shi R, 2001, BRIT J CANCER, V85, P991, DOI 10.1054/bjoc.2001.1961
   Sieh W, 2006, CANCER CAUSE CONTROL, V17, P187, DOI 10.1007/s10552-005-0454-8
   Silig Y, 2006, CANCER INVEST, V24, P41, DOI 10.1080/07357900500449579
   SLATTERY ML, 1993, CANCER CAUSE CONTROL, V4, P559, DOI 10.1007/BF00052432
   Soffritti M, 2002, ANN NY ACAD SCI, V982, P46, DOI 10.1111/j.1749-6632.2002.tb04924.x
   Stattin P, 2004, J CLIN ONCOL, V22, P3104, DOI 10.1200/JCO.2004.10.105
   Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910
   Stattin P, 2004, CANCER CAUSE CONTROL, V15, P1095, DOI 10.1007/s10552-004-1480-7
   Stattin P, 2004, INT J CANCER, V108, P418, DOI 10.1002/ijc.11572
   Stevens VL, 2005, CANCER CAUSE CONTROL, V16, P643, DOI 10.1007/s10552-005-0384-5
   Stewart RE, 1999, J OCCUP ENVIRON MED, V41, P1079, DOI 10.1097/00043764-199912000-00012
   Suzuki K, 2003, CANCER-AM CANCER SOC, V98, P1411, DOI 10.1002/cncr.11639
   Taylor ML, 2005, FAM MED, V37, P506
   Thellenberg-Karlsson C, 2006, CLIN CANCER RES, V12, P1936, DOI 10.1158/1078-0432.CCR-05-0269
   Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660
   Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545
   Trummer H, 2002, HUM REPROD, V17, P1554, DOI 10.1093/humrep/17.6.1554
   Tseng M, 2005, AM J CLIN NUTR, V81, P1147
   Tuohimaa P, 2005, J STEROID BIOCHEM, V93, P183, DOI 10.1016/j.jsbmb.2004.12.009
   Tuohimaa P, 2004, INT J CANCER, V108, P104, DOI 10.1002/ijc.11375
   van den Brandt PA, 2003, CANCER EPIDEM BIOMAR, V12, P866
   van Gils CH, 2002, CANCER EPIDEM BIOMAR, V11, P1279
   van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y
   Van Maele-Fabry G, 2004, INT ARCH OCC ENV HEA, V77, P559, DOI 10.1007/s00420-004-0548-8
   vanderGulden JWJ, 1997, PROSTATE, V30, P107, DOI 10.1002/(SICI)1097-0045(19970201)30:2<107::AID-PROS6>3.0.CO;2-L
   Vatten LJ, 1997, CANCER EPIDEM BIOMAR, V6, P967
   Verougstraete V, 2003, J TOXICOL ENV HEAL B, V6, P227, DOI 10.1080/10937400306465
   Wadelius M, 1999, PHARMACOGENETICS, V9, P333, DOI 10.1097/00008571-199906000-00008
   Wahle KWJ, 2004, PROG LIPID RES, V43, P553, DOI 10.1016/j.plipres.2004.08.002
   Weinstein SJ, 2005, JNCI-J NATL CANCER I, V97, P396, DOI 10.1093/jnci/dji045
   Weston T L, 2000, INT J OCCUP ENVIRON HEALTH, V6, P194
   Wong O, 2000, REGUL TOXICOL PHARM, V32, P78, DOI 10.1006/rtph.2000.1410
   Xu JF, 2002, CANCER RES, V62, P2253
   Yan L, 2005, INT J CANCER, V117, P667, DOI 10.1002/ijc.21266
   Zeegers MP, 2004, CANCER EPIDEM BIOMAR, V13, P1765
   Zeegers MPA, 2005, CANCER EPIDEM BIOMAR, V14, P1490, DOI 10.1158/1055-9965.EPI-04-0771
   Zeegers MPA, 2004, J OCCUP ENVIRON MED, V46, P271, DOI 10.1097/01.jom.0000116961.48464.6b
   Zeigler-Johnson C, 2004, CANCER RES, V64, P8461, DOI 10.1158/0008-5472.CAN-04-1651
   Zhao H, 2005, CANCER-AM CANCER SOC, V104, P44, DOI 10.1002/cncr.21135
   Zhu K, 2004, AM J EPIDEMIOL, V159, P978, DOI 10.1093/aje/kwh139
NR 223
TC 43
Z9 57
U1 0
U2 31
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1093-7404
EI 1521-6950
J9 J TOXICOL ENV HEAL B
JI J. Toxicol. Env. Health-Pt b-Crit. Rev.
PD MAR-APR 15
PY 2008
VL 11
IS 3-4
BP 242
EP 259
DI 10.1080/10937400701873548
PG 18
WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology
GA 299JZ
UT WOS:000255753200007
PM 18368555
DA 2025-04-28
ER

PT J
AU Venables, MC
   Hulston, CJ
   Cox, HR
   Jeukendrup, AE
AF Venables, Michelle C.
   Hulston, Carl J.
   Cox, Hannah R.
   Jeukendrup, Asker E.
TI Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE tea catechins; substrate metabolism; oralglucose-tolerance test; moderate-intensity exercise; men
ID insulin sensitivity; exercise intensity; metabolism; muscle; performance; endurance; caffeine; mice; supplementation; resistance
AB Background: Green tea consumption is reportedly associated with various health-promoting properties. For example, it has been shown to promote fat oxidation in humans at rest and to prevent obesity and improve insulin sensitivity in mice. Objective: We investigated the effects of acute ingestion of green tea extract (GTE) on glucose tolerance and fat oxidation during moderate-intensity exercise in humans. Design: Two studies were performed, both with a counter-balanced crossover design. In study A, 12 healthy men performed a 30-min cycling exercise at 60% of maximal oxygen consumption (<(V)over dot>O(2)max) before and after supplementation. In study B, 11 healthy men took an oral-glucose-tolerance test before and after supplementation. In the 24-h period before the experimental trials, participants ingested 3 capsules containing either GTE (total: 890 +/- 13 mg polyphenols and 366 +/- 5 mg EGCG) or a corn-flour placebo (total: 1729 +/- 22 mg). Results: Average fat oxidation rates were 17% higher after ingestion of GTE than after ingestion of placebo (0.41 +/- 0.03 and 0.35 +/- 0.03 g/min, respectively; P < 0.05). Moreover, the contribution of fat oxidation to total energy expenditure was also significantly higher, by a similar percentage, after GTE supplementation. The insulin area under the curve decreased in both the GTE and placebo trials (3612 +/- 301 and 4280 +/- 309 mu IU/dL (.) 120 min, respectively; P < 0.01), and there was a concomitant increase of 13% in insulin sensitivity. Conclusions: Acute GTE ingestion can increase fat oxidation during moderate-intensity exercise and can improve insulin sensitivity and glucose tolerance in healthy young men.
C1 [Venables, Michelle C.; Hulston, Carl J.; Cox, Hannah R.; Jeukendrup, Asker E.] Univ Birmingham, Sch Sport & Exercise Sci, Human Performance Lab, Birmingham B15 2TT, W Midlands, England.
C3 University of Birmingham
RP Jeukendrup, AE (corresponding author), Univ Birmingham, Sch Sport & Exercise Sci, Human Performance Lab, Birmingham B15 2TT, W Midlands, England.
EM a.e.jeukendrup@bham.ac.uk
CR ARNER P, 1990, J CLIN INVEST, V85, P893, DOI 10.1172/JCI114516
   Cameron-Smith D, 2003, AM J CLIN NUTR, V77, P313, DOI 10.1093/ajcn/77.2.313
   CAMPBELL PJ, 1992, AM J PHYSIOL, V263, P0
   COSTILL DL, 1978, MED SCI SPORT EXER, V10, P155
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Horowitz JF, 1997, AM J PHYSIOL-ENDOC M, V273, PE768, DOI 10.1152/ajpendo.1997.273.4.E768
   Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005
   IVY JL, 1979, MED SCI SPORT EXER, V11, P6
   Jeukendrup AE, 1998, INT J SPORTS MED, V19, P293, DOI 10.1055/s-2007-971921
   Jeukendrup AE, 2005, INT J SPORTS MED, V26, PS28, DOI 10.1055/s-2004-830512
   KUIPERS H, 1985, INT J SPORTS MED, V6, P197, DOI 10.1055/s-2008-1025839
   Lu H, 2003, DRUG METAB DISPOS, V31, P572, DOI 10.1124/dmd.31.5.572
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   McArdle WD, 2000, ESSENTIALS EXERCISE, V2nd, P0
   Murase T, 2006, AM J PHYSIOL-REG I, V290, PR1550, DOI 10.1152/ajpregu.00752.2005
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Murase T, 2005, AM J PHYSIOL-REG I, V288, PR708, DOI 10.1152/ajpregu.00693.2004
   Potenza MA, 2007, AM J PHYSIOL-ENDOC M, V292, PE1378, DOI 10.1152/ajpendo.00698.2006
   ROMIJN JA, 1993, AM J PHYSIOL, V265, PE380, DOI 10.1152/ajpendo.1993.265.3.E380
   Shimotoyodome A, 2005, MED SCI SPORT EXER, V37, P1884, DOI 10.1249/01.mss.0000178062.66981.a8
   van Loon LJC, 2001, J PHYSIOL-LONDON, V536, P295, DOI 10.1111/j.1469-7793.2001.00295.x
   Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200
   Watanabe J, 1998, BIOSCI BIOTECH BIOCH, V62, P532, DOI 10.1271/bbb.62.532
   WOLFE RR, 1990, AM J PHYSIOL, V258, PE382, DOI 10.1152/ajpendo.1990.258.2.E382
   Wu LY, 2004, J AGR FOOD CHEM, V52, P643, DOI 10.1021/jf030365d
   Wu LY, 2004, EUR J NUTR, V43, P116, DOI 10.1007/s00394-004-0450-x
   Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200
NR 27
TC 212
Z9 238
U1 0
U2 47
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA
SN 0002-9165
EI 
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAR 15
PY 2008
VL 87
IS 3
BP 778
EP 784
DI 10.1093/ajcn/87.3.778
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 273KA
UT WOS:000253927700032
PM 18326618
DA 2025-04-28
ER

PT J
AU Boon, N
AF Boon, Niels
TI Health Potential for Functional Green Teas?
SO INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH
LA English
DT Article; Proceedings Paper
DE Green tea; catechins; health benefits
ID randomized controlled-trial; blood-glucose levels; body-weight loss; fat oxidation; black tea; endothelial function; energy-expenditure; insulin-resistance; catechin-polyphenols; caffeine intake
AB Obesity is a major health problem in the developed and developing world. Many "functional" foods and ingredients are advocated for their effects on body composition but few have consistent scientific support for their efficacy. However, an increasing amount of mechanistic and clinical evidence is building for green tea. The tea plant is naturally rich in a group of antioxidants known as catechins. Unlike black tea, green tea production involves little processing and fermentation and therefore, green tea brews are rich in catechins. Green tea has been suggested to have a number of potential health benefits in areas such as cardiovascular disease, cancer prevention, glucose homeostasis and dental health. Although there is some promising evidence in all of these areas, more data from human intervention trials are needed. A lot of attention has lately been focused on the beneficial effects of green tea on body composition and particularly visceral fat, which has been shown to have a strong link with different components of the metabolic syndrome such as cardiovascular disease and type 2 diabetes. Most, but not all, of the positive results come from a number Asian studies, in which overweight subjects (men and women) consumed green tea for approximately 12 weeks. Finally, green tea may also have measurable acute effects oil energy metabolism and fat oxidation and in particular during physical activity, as evidenced by other studies specifically looking at these endpoints. Small cumulative effects on energy metabolism could also be responsible for the longer-tem effects of green tea on body composition, and these long-term effects may also be most apparent in the context of moderate physical activity. However, more research is needed to further clarify the exact mechanisms of action and to extrapolate these findings to non-Asian populations.
C1 [Boon, Niels] Unilever Res Labs, Vlaardingen, Netherlands.
   [Boon, Niels] Lipton Inst Tea, Vlaardingen, Netherlands.
C3 Unilever
RP Boon, N (corresponding author), Unilever Res Labs, Vlaardingen, Netherlands.
EM niels.boon@unilever.com
CR Alexopoulos N, 2008, EUR J CARDIOV PREV R, V15, P300, DOI 10.1097/HJR.0b013e3282f4832f
   Astill C, 2001, J AGR FOOD CHEM, V49, P5340, DOI 10.1021/jf010759+
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   *FOOD STAND AG, 2001, COMM TOX CHEM FOOD C, V0, P0
   Fukino Y, 2008, EUR J CLIN NUTR, V62, P953, DOI 10.1038/sj.ejcn.1602806
   Fukino Y, 2005, J NUTR SCI VITAMINOL, V51, P335, DOI 10.3177/jnsv.51.335
   Gardner EJ, 2007, EUR J CLIN NUTR, V61, P3, DOI 10.1038/sj.ejcn.1602489
   Hamilton-Miller JMT, 2001, J MED MICROBIOL, V50, P299, DOI 10.1099/0022-1317-50-4-299
   Harada U, 2005, J HEALTH SCI, V51, P248, DOI 10.1248/jhs.51.248
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hirasawa M, 2006, CARIES RES, V40, P265, DOI 10.1159/000092236
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Hsu TF, 2006, EUR J CLIN NUTR, V60, P1330, DOI 10.1038/sj.ejcn.1602464
   Hughes LAE, 2008, AM J CLIN NUTR, V88, P1341, DOI 10.3945/ajcn.2008.26058
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   Jochmann N, 2008, BRIT J NUTR, V99, P863, DOI 10.1017/S0007114507838992
   Jones C, 1999, COMMUNITY DENT HLTH, V16, P68
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Kajimoto O, 2005, J HEALTH SCI, V51, P161, DOI 10.1248/jhs.51.161
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Kataoka K, 2004, PROGRESS IN MEDICINE, V24, P3358
   Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636
   Kim W, 2006, CIRC J, V70, P1052, DOI 10.1253/circj.70.1052
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Liu T, 2000, ZHONGHUA KOU QIANG YI XUE ZA ZHI, V35, P383
   MacKenzie T, 2007, METABOLISM, V56, P1340, DOI 10.1016/j.metabol.2007.05.018
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Matsuyama T, 2008, OBESITY, V16, P1338, DOI 10.1038/oby.2008.60
   Moon HS, 2007, CHEM-BIOL INTERACT, V167, P85, DOI 10.1016/j.cbi.2007.02.008
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   *NHS CRD, 2000, 18 NHS CRD U YORK CT, V0, P0
   OOSHIMA T, 1994, CARIES RES, V28, P146, DOI 10.1159/000261636
   Ota N, 2005, J HEALTH SCI, V51, P233, DOI 10.1248/jhs.51.233
   Polychronopoulos E, 2008, EUR J NUTR, V47, P10, DOI 10.1007/s00394-007-0690-7
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Ryu OH, 2006, DIABETES RES CLIN PR, V71, P356, DOI 10.1016/j.diabres.2005.08.001
   SARIS WHM, 1995, INT J OBESITY, V19, P0
   Song YQ, 2005, J AM COLL NUTR, V24, P376, DOI 10.1080/07315724.2005.10719488
   Stangl V, 2006, MOL NUTR FOOD RES, V50, P218, DOI 10.1002/mnfr.200500118
   Takashima S, 2004, PROGRESS IN MEDICINE, V24, P3371
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Tsuneki Hiroshi, 2004, BMC PHARMACOLOGY, V4, P18, DOI 10.1186/1471-2210-4-18
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Vermeer MA, 2008, J AGR FOOD CHEM, V56, P12031, DOI 10.1021/jf8022035
   WANG M, 2007, 4 AS OC C OB, V115, P0
   WEI SHY, 1989, NUTRITION, V5, P237
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Widlansky ME, 2007, J AM COLL NUTR, V26, P95, DOI 10.1080/07315724.2007.10719590
   Wolfram S, 2007, J AM COLL NUTR, V26, P373S, DOI 10.1080/07315724.2007.10719626
   Wu CD, 2002, NUTRITION, V18, P443, DOI 10.1016/S0899-9007(02)00763-3
   Wu CH, 2003, OBES RES, V11, P1088, DOI 10.1038/oby.2003.149
   Yang CS, 2007, TOXICOL APPL PHARM, V224, P265, DOI 10.1016/j.taap.2006.11.024
   You SQ, 1993, CHUNG HUA KOU CHIANG, V28, P197
   YU H, 1995, J DENT, V23, P101, DOI 10.1016/0300-5712(95)98975-9
NR 65
TC 12
Z9 13
U1 3
U2 72
PU VERLAG HANS HUBER
PI BERN 9
PA LANGGASS-STRASSE 76, CH-3000 BERN 9, SWITZERLAND
SN 0300-9831
EI 1664-2821
J9 INT J VITAM NUTR RES
JI Int. J. Vitam. Nutr. Res.
PD DEC 15
PY 2008
VL 78
IS 6
BP 275
EP 281
DI 10.1024/0300-9831.78.6.275
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 484IR
UT WOS:000269038400005
PM 19685436
DA 2025-04-28
ER

